Goose Astrovirus

Overview and Taxonomy of Goose Astrovirus (GAstV)

Emergence and Economic Significance

Goose astrovirus (GAstV) is an emerging, non‑enveloped, positive‑sense single‑stranded RNA virus that belongs to the family Astroviridae, genus Avastrovirus. It was first identified as the causative agent of a devastating gout‑like disease in goslings in China in 2016–2017, although retrospective surveillance suggests the virus may have been circulating earlier [1, 22, 24, 38]. Since then, GAstV has spread explosively across more than 17 provinces in eastern China, causing mortality rates of 10–60% in affected flocks and inflicting multi‑billion‑dollar losses on the global goose industry [1, 15, 22]. The disease is most severe in goslings 1–3 weeks of age, with typical signs including visceral and articular urate deposition, kidney swelling, and profound immune suppression [1, 10, 16]. Critically, GAstV is not confined to geese; it has demonstrated the ability to infect ducks (including Muscovy and Cherry Valley ducklings) and chickens, raising concerns about cross‑species transmission and the potential for broader poultry health impacts [12, 20, 22, 31, 34, 35, 37]. The World Organisation for Animal Health (WOAH) now recognizes GAstV as an emerging transboundary pathogen of waterfowl, necessitating urgent taxonomic clarity and global surveillance.

Taxonomic Position and Genotypic Classification

GAstV is classified within the genus Avastrovirus, which currently includes three recognized species based on the host and genome organization: Avastrovirus 1 (AAstV-1), Avastrovirus 2 (AAstV-2), and Avastrovirus 3 (AAstV-3) [22, 29]. Extensive whole‑genome phylogenetic analyses of over 183 Chinese isolates have unequivocally divided GAstV into two major genotypes: GAstV-I (also referred to as GAstV-1) and GAstV-II (GAstV-2) [1, 3, 18, 28, 29]. This bipartite classification is supported by high bootstrap values in both complete‑genome and ORF2‑based trees, and by nucleotide identities that typically fall below 60% between the two groups [23, 28]. GAstV-I is more closely related to turkey astrovirus type 2 (TAstV-2) and duck astrovirus type IV (DAstV-IV), while GAstV-II clusters with DAstV-II and TAstV-II, placing GAstV-II within the AAstV-3 species and GAstV-I within AAstV-1 [29, 34, 39]. This genetic divergence is not merely academic; the two genotypes exhibit distinct pathological signatures: GAstV-II is consistently associated with severe visceral and joint gout, whereas GAstV‑I strains can cause enteritis, mild nephritis, or asymptomatic infection, and their role in gout has been controversial until recent isolation studies confirmed that some GAstV‑I strains can indeed produce typical urate deposition [4, 5, 14, 23, 26].

Sub‑genotypic Diversity and Molecular Markers

Further resolution within each genotype has revealed multiple subgroups. Based on complete capsid (ORF2) sequences, GAstV-I divides into subgroups GI‑a and GI‑b (or, equivalently, GAstV‑1a and GAstV‑1b), with characteristic amino‑acid deletions at positions 652–653 and 706 in GI‑a serving as reliable molecular markers [3, 14]. GAstV‑II exhibits even greater sub‑branching: at least four subgenotypes, GII‑a, GII‑b, GII‑c, and GII‑d, have been delineated, with GII‑d (sometimes called subgroup 1a in other nomenclatures) becoming the dominant clade in China since 2017 [3, 19, 25, 28, 42]. Key mutations in the capsid spike domain, such as E456D and L540Q, discriminate GII‑c from GII‑d and appear to correlate with enhanced virulence and tissue tropism [11, 19, 28]. The capsid protein (VP90/VP70/VP27) is the primary structural and antigenic protein, and its encoding ORF2 shows 25–40% amino‑acid divergence between genotypes, whereas intra‑genotype ORF2 similarity typically exceeds 95% [18, 23]. This level of variability underpins the need for genotype‑specific diagnostic assays and vaccine strategies.

Evolutionary Dynamics and Recombination

Bayesian phylogenetic analyses indicate that GAstV‑II likely emerged as a distinct lineage around January 2010 (95% HPD: 2008–2012), while GAstV‑I appears to have an older common ancestor dating to approximately April 1985 [29]. The mean nucleotide substitution rate for the capsid gene of GAstV is estimated at 1.42 × 10⁻³ substitutions/site/year, which is typical of avian astroviruses [29, 34]. A remarkable feature of GAstV evolution is the high frequency of natural recombination. Among 183 complete genomes analyzed, 27 distinct recombination events were identified, with the majority occurring within GAstV‑II, especially in the GII‑c subgenotype [3, 25]. Recombination breakpoints are most frequently located in ORF1b and ORF2; inter‑genotype recombination (e.g., GAstV‑I × GAstV‑II) is rare but has been documented [17]. Codon usage bias analyses reveal that GAstV‑II exhibits a weaker codon bias than GAstV‑I, conferring greater translational flexibility across different host species (geese, ducks, chickens) [11, 13]. Additionally, purifying (negative) selection dominates the majority of the genome, although several positively selected residues in the capsid spike region (e.g., positions 456, 540) may drive immune evasion and host adaptation [25, 42].

Antigenic Features and Serological Relationships

Despite genetic divergence, cross‑neutralization tests using hyperimmune sera against representative GAstV‑II isolates show that antigenic relatedness values (R) range from 62% to 86%, indicating that no major antigenic differences exist among circulating field strains [30]. Monoclonal antibody (mAb) mapping has identified several linear B‑cell epitopes in the capsid protein. For GAstV‑II, conserved epitopes include ³³QKVY³⁶, ¹⁵³NTAGPESIDT¹⁶², and ⁴⁴³ESCSFLVF⁴⁵⁰, while GAstV‑I has a unique epitope ³⁹⁴SNREVQITQL⁴⁰³ [2, 8, 9, 36, 40]. These epitopes are largely located in the S (shell) and P2 (protruding) domains of the capsid and serve as the basis for developing genotype‑specific serological ELISAs and point‑of‑care detection strips [8, 9, 32, 33, 41]. GAstV‑II strains induce strong humoral responses that can be detected by virus‑neutralization tests or competitive ELISA, with seroprevalence rates reaching 71% in some Chinese flocks [21, 30]. Importantly, GAstV does not currently fall under any formal WOAH‑listed disease category, but its rapid spread through the live‑gosling trade and its documented ability to infect multiple avian species underscore the urgency of official recognition and harmonized taxonomy.

Relationship with Other Avian Astroviruses

Phylogenetically, GAstV‑I forms a clade with duck astrovirus (DAstV) type IV and turkey astrovirus (TAstV) type 2, whereas GAstV‑II groups with DAstV‑II and TAstV‑II [28, 29]. This positioning implies multiple host‑switch events in the evolutionary history of avian astroviruses. The capsid protein of GAstV shares 37% sequence similarity with the corresponding protein of duck astrovirus, but the P2 domain is only 30% conserved, indicating strong host‑specific adaptation [7]. Natural co‑infection of GAstV‑I and GAstV‑II in the same gosling is common, occurring in 15–50% of clinical cases depending on region [6, 7, 18, 27]. Co‑infection exacerbates pathological damage, particularly in the kidneys and spleen, and may facilitate recombination events that accelerate viral evolution [18]. These findings highlight that GAstV taxonomy must be considered not as a static classification but as a dynamic framework reflecting ongoing adaptation, reassortment, and host expansion.

In summary, GAstV comprises two major genotypes (GAstV‑I and GAstV‑II) with multiple subgenotypes that display distinct genetic, antigenic, and pathogenic properties. The virus is a rapidly evolving recombinant RNA pathogen with significant cross‑species potential. A unified nomenclature, preferably endorsed by the International Committee on Taxonomy of Viruses (ICTV) and WOAH, is urgently needed to support global surveillance, risk assessment, and the development of effective vaccines and diagnostics. The following sections will delve deeper into the molecular virology, pathogenesis, and control strategies for this emerging waterfowl pathogen.

Molecular Pathogenesis and Virulence Mechanisms of GAstV

The molecular pathogenesis of Goose Astrovirus (GAstV) represents a brilliantly orchestrated interplay between viral subversion of host cellular machinery and the host's multifaceted innate immune responses. Since its emergence as a causative agent of devastating gout in goslings, the virus has demonstrated a sophisticated capacity to hijack purine metabolism, induce targeted cellular injury, and manipulate antiviral signaling pathways to establish a productive infection. Understanding these mechanisms at the molecular level is not merely an academic exercise but a critical prerequisite for the rational design of antiviral therapeutics and effective vaccines.

Viral Entry, Host Factor Recruitment, and the Initiation of Infection

The initial stages of GAstV infection are governed by specific molecular interactions between the viral capsid and host cell surface proteins which dictate tissue tropism and the efficiency of viral entry. The capsid protein, encoded by ORF2, is the primary determinant of these interactions, undergoing a complex post-translational maturation process essential for infectivity. In a baculovirus expression system, the full-length ORF2 of GAstV-1 undergoes proteolytic cleavage to yield mature core (40/43 kDa) and spike (25/27 kDa) fragments, a process critical for the self-assembly of virus-like particles (VLPs) and likely reflecting the natural maturation pathway required for the virus to acquire its infectious conformation [46]. This cleavage generates distinct structural domains, a core domain (VP34/VP35), a spike domain (VP27), and a C-terminal acidic domain, each contributing to different facets of the viral life cycle, from genome packaging to receptor engagement.

Among the host proteins exploited by GAstV for entry, the 70 kDa heat shock protein 5 (HSPA5) emerges as a critical candidate. Through viral overlay protein blot assay (VOPBA) and LC-MS/MS, HSPA5 was identified as a membrane-associated protein on Leghorn Male Hepatoma (LMH) cells capable of interacting with the GAstV capsid [44]. Computational docking models refined this interaction to seven specific residues on the viral P2 protein (THR124, ILE22, VAL24, TRP51, PRO66, GLN100, and VAL125) and twelve residues on HSPA5 (including ARG2, HIS3, and several leucine residues in the N-terminal region) [44]. While HSPA5 is traditionally viewed as an endoplasmic reticulum (ER)-resident chaperone, its presence on the cell surface suggests that GAstV co-opts this protein as a docking or entry receptor, analogous to mechanisms described for other viruses. This interaction may facilitate viral internalization or initiate signaling cascades that prime the cellular environment for replication.

Beyond entry, the virus requires a supportive intracellular environment, and it achieves this by commandeering structural proteins of the host cytoskeleton. The intermediate filament protein vimentin (VIM) was identified as a binding partner of the GAstV-2 structural protein VP70 through immunoprecipitation and mass spectrometry [49]. The interaction is mapped to a discrete region spanning amino acid residues 399–413 of VP70, and its disruption via point mutation significantly impairs viral replication [49]. Laser confocal microscopy revealed that VP70 expression induces a dramatic rearrangement of the vimentin network, causing it to aggregate from a uniform grid-like distribution toward the perinuclear region [49]. This reorganization concentrates viral RNA within the aggregated vimentin cage, effectively creating a viral replication complex or "viroplasm." The process is dependent on increased vimentin phosphorylation triggered by GAstV infection, and pharmacological blockade of this rearrangement with acrylamide severely curtails viral replication [49]. This dependency highlights that GAstV does not merely interact with the cytoskeleton passively but actively remodels it to create a protected niche for genome replication and virion assembly.

Modulation of Host Metabolism: The Hijacking of Purine Biosynthesis and Uric Acid Dysregulation

The hallmark of GAstV pathogenesis, visceral and articular gout, is a direct consequence of profound hyperuricemia, which the virus orchestrates through a multi-pronged assault on host metabolic pathways. The virus strategically upregulates key enzymes in the hepatic purine catabolic cascade, shifting the metabolic flux toward massive uric acid production while simultaneously impairing renal excretory function. This is not a passive consequence of tissue destruction but an active, virus-driven reprogramming of host biochemistry.

Infection with GAstV leads to significantly increased activities and mRNA levels of xanthine dehydrogenase (XOD) and adenosine deaminase (ADA) in the liver, the central organs for uric acid synthesis in birds [55]. Additionally, the expression of phosphoribosyl pyrophosphate amidotransferase (PPAT) and phosphoribosyl pyrophosphate synthetase 1 (PRPS1), rate-limiting enzymes in de novo purine synthesis, is upregulated, indicating that the virus stimulates the entire pathway from nucleotide synthesis to the terminal conversion of xanthine to uric acid [55]. This is corroborated by transcriptomic analyses of infected goose embryo fibroblasts (GEFs), which identified ADA as a highly differentially expressed gene [45]. The connection between ADA and GAstV replication is particularly compelling. GAstV-II infection promotes the production of goose ADA (gADA) without altering its subcellular distribution, and crucially, ectopic expression of gADA significantly enhances viral capsid protein expression and viral loads [43]. Conversely, siRNA-mediated knockdown of gADA suppresses replication [43]. The mechanism involves a direct physical interaction between gADA and the viral capsid protein, specifically its C-terminal domain, suggesting that ADA is co-opted by the virus as a proviral host factor that facilitates some step in the replication cycle [43].

The consequences of this metabolic hijacking are devastating. The accumulation of uric acid overwhelms the renal excretory capacity, which is itself compromised by the virus. GAstV infection reduces the mRNA levels of multidrug resistance-associated protein 4 (MRP4), a key renal transporter responsible for urate secretion, and decreases Na-K-ATPase activity in kidney tissues, impairing the energy-dependent processes of tubular secretion [55]. The resultant hyperuricemia drives the crystallization of urate in joints and on visceral surfaces, the defining pathological feature of gout.

Further amplifying this metabolic catastrophe, recent evidence implicates the gut microbiome as an ancillary contributor to the urate burden. Infection with GAstV genotype 2 significantly alters the composition of the gut microbiota, enriching pro-inflammatory bacterial populations while depleting beneficial short-chain fatty acid (SCFA)-producing bacteria [47]. More specifically, the microbial pathways involved in urate production are significantly enhanced in infected goslings [47]. This suggests that the virus's influence on host metabolism extends beyond the direct manipulation of hepatic and renal enzymes to include the remote regulation of the intestinal microbiome, which then contributes an additional stream of purine substrates and pre-formed urate to the systemic circulation. The interplay between viral replication, metabolic dysregulation, and gut dysbiosis creates a self-reinforcing loop that drives the extreme hyperuricemia characteristic of fatal gosling gout.

Induction of Cellular Injury: Apoptosis, Endoplasmic Reticulum Stress, and Inflammatory Signaling

GAstV induces extensive tissue damage in the kidney, liver, and spleen through the coordinated activation of apoptotic pathways, endoplasmic reticulum (ER) stress, and exuberant inflammatory responses. These processes are not merely destructive epiphenomena but are intricately linked to the viral replication strategy and the pathological manifestations of the disease.

In goose embryonic kidney (GEK) cells, GAstV infection triggers a robust apoptotic response mediated by the mitochondrial (intrinsic) pathway. This is characterized by upregulated expression of the pro-apoptotic protein Bax, activation of caspase-9 and caspase-3, and release of cytochrome c from mitochondria into the cytosol, alongside a corresponding decrease in the anti-apoptotic protein Bcl-2 [48]. The apoptotic machinery is further amplified in gosling hepatocytes, where infection also instigates ER stress. Electron microscopy of infected hepatocytes reveals expansion of the ER lumen and peripheral aggregation of chromatin, classic morphological signs of ER stress [51]. At the molecular level, the virus disrupts ER calcium homeostasis by increasing the expression of inositol 1,4,5-trisphosphate receptors (IP3R) and ryanodine receptors (RYR), calcium release channels, while simultaneously decreasing the expression of sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA), the calcium re-uptake channel [51]. This leads to calcium depletion from the ER, a potent trigger for the unfolded protein response (UPR). The virus activates all three canonical arms of the UPR, as evidenced by the upregulation of GRP78, IRE1α, PERK, ATF6, eIF2α, ATF4, and CHOP [51]. The pro-apoptotic transcription factor CHOP, along with TRAF2 and JNK activation, provides a direct link between sustained ER stress and the execution of apoptosis in hepatic cells. Correlation analyses have established a significant relationship among the expression of ER stress genes, apoptotic genes, and the degree of liver injury, confirming that ER stress-induced apoptosis is a major driver of hepatic pathology [51].

Concurrently, GAstV infection ignites a potent inflammatory response that contributes to both tissue damage and the febrile aspects of the disease. In GEK cells, the virus activates the RIG-I/MDA5 signaling pathway, leading to the upregulation of downstream adaptor proteins MAVS, IRF7, and the master inflammatory transcription factor NF-κB [48]. This cascade results in the massive release of pro-inflammatory cytokines including IL-6, IL-8, and TNF-α [48]. Furthermore, GAstV infection activates the NLRP3 inflammasome pathway, which catalyzes the cleavage of pro-IL-1β into its active, secreted form (IL-1β) [48]. The liberation of IL-1β is a critical event, as it is a pyrogenic cytokine that also promotes systemic inflammation and has been directly linked to gouty inflammation in human disease. In renal tissues, this inflammatory storm is further characterized by upregulation of IL-1β, IL-6, IL-10, TGF-β, and iNOS, and is associated with fibrotic remodeling observed through Masson and Picrosirius Red staining [16]. The inducible nitric oxide synthase (iNOS) is particularly noteworthy; while its product, nitric oxide (NO), is antiviral in nature, excessive NO contributes to cellular injury and oxidative stress. In an experimental model, the iNOS inhibitor aminoguanidine (AG) significantly reduced mortality and kidney lesions in GAstV-2-infected goslings, an effect attributed to reduced inflammation and autophagy rather than a direct reduction in viral load [52]. This underscores that the disease pathology is driven as much by the host's dysregulated inflammatory response as by the virus itself.

Innate Immune Recognition, Antagonism, and Proviral Host Factors

GAstV is sensed by the host's pattern recognition receptors (PRRs), which initiate a signaling cascade intended to restrict viral replication. However, the virus has evolved countermeasures that subvert these responses, and in some cases, exploits components of the interferon (IFN) system to its own advantage.

The RIG-I and MDA5 receptors, key sensors of viral RNA, are activated upon GAstV infection, leading to the expression of type I interferons (IFN-α/β) and a suite of interferon-stimulated genes (ISGs) [54]. Among the induced ISGs, the 2',5'-oligoadenylate synthetase-like protein (OASL) plays a particularly intriguing role. The ORF2 capsid protein of GAstV, specifically the P2 domain, is a potent inducer of OASL both in vitro and in vivo [56]. OASL, in turn, functions as a restriction factor that feeds back to limit viral replication, providing a classic example of a negative-feedback loop within the innate immune system [56]. The acidic C-terminal domain of ORF2 attenuates this OASL induction, suggesting that the capsid protein has a built-in regulatory mechanism to dampen the host's antiviral response [56]. This self-limiting property of OASL induction may partly explain the self-limiting nature of astrovirus infections in general.

In a striking example of host factor subversion, GAstV has been shown to positively regulate the interferon-induced protein with tetratricopeptide repeats 5 (IFIT5) to boost its own replication. IFIT5 mRNA and protein levels are strongly induced by GAstV infection in GEF cells, particularly at 12 hours post-infection [50]. Paradoxically, overexpression of goose IFIT5 (gIFIT5) significantly enhances viral capsid protein expression and viral titers, while its knockdown suppresses replication [50]. This places IFIT5 firmly in the category of a proviral host factor that GAstV actively upregulates to facilitate its own multiplication, a phenomenon reminiscent of how some viruses co-opt certain ISGs to stabilize viral RNA or enhance translation.

The response of immune cells to GAstV is complex and cell-type specific. The virus can infect both CD4⁺ and CD8⁺ T lymphocytes, as well as macrophages, but with divergent outcomes [53]. In lymphocytes, GAstV infection is detrimental: it suppresses proliferation induced by Concanavalin A and lipopolysaccharide, and increases the rate of apoptosis, correlating with increased expression of the death receptor Fas [53]. This lymphocytotoxicity likely contributes to the immunosuppression observed in infected goslings, increasing susceptibility to secondary infections. Conversely, GAstV infection of macrophages enhances their phagocytic activity, increases the production of reactive oxygen species (ROS) and NO, and induces a pro-inflammatory (M1) polarization state [53]. Macrophages thus appear to mount an effective antiviral response, acting as a critical line of defense. This dichotomy between lymphocyte depletion and macrophage activation is a key immunopathological feature of the disease.

Genetic and Structural Basis for Virulence and Genotypic Dominance

The molecular basis for the differential virulence observed between GAstV-1 and GAstV-2, and the dominance of GAstV-2 in the field, is beginning to be elucidated at the genetic and structural level. Comparative genomic analyses have identified specific amino acid signatures in the capsid protein that correlate with genotype and pathogenicity. For instance, characteristic deletions at positions 652-653 and 706 in the capsid protein serve as reliable molecular markers for the GI a and GI b subgroups of GAstV-1 [3]. For GAstV-2, specific mutations in the capsid P2 domain, such as E456D, A464N, and L540Q, differentiate the dominant sub-genotype IId from other lineages [19, 42].

The structural organization of the capsid protein itself underlies functional specialization. The P2 domain, which forms the outermost "spike" of the capsid, is the primary target of neutralizing antibodies. Novel linear B-cell neutralizing epitopes have been identified precisely within this domain, including ⁴⁴³ESCSFLVF⁴⁵⁰ and ⁴²⁵QVTPSLVYNF⁴³⁴ [40]. Variation in this domain between genotypes explains the lack of cross-neutralization and the ability of GAstV-2 to evade pre-existing immunity to GAstV-1, contributing to its epidemiological success [11]. Conversely, the core (S) domain is more conserved and harbors epitopes like ¹MADRA⁵ and ³⁶YKPQKLPMKA⁴⁵, which are targeted by monoclonal antibodies used in diagnostic assays but do not, on their own, confer protective immunity [8].

At a more fundamental level, the molecular evolution of GAstV-2 favors its persistence. Analysis of codon usage bias reveals that GAstV-2 has a weaker codon usage bias than GAstV-1, meaning it uses a broader range of synonymous codons [11]. This flexibility allows GAstV-2 to adapt more readily to the translational machinery of different host tissues and species. Furthermore, the spike protein of GAstV-2 exhibits significantly lower variability (as measured by Shannon entropy) than that of GAstV-1 [11]. This genetic and structural stability reduces the need for frequent antigenic change, allowing the virus to persist in host populations without undergoing constant immune-driven evolution. In essence, GAstV-2 has struck a successful evolutionary balance: it is adaptable enough to maintain broad host tropism yet stable enough to avoid antibody-mediated clearance, ensuring its continued dominance as the primary etiological agent of gosling gout. The World Organisation for Animal Health (WOAH) recognizes emerging astrovirus infections as a significant threat to poultry, and the molecular mechanisms described here underscore the need for continuous surveillance and vaccine development to counter this economically devastating pathogen.

Epidemiology, Host Range, and Global Distribution of GAstV

Emergence and Initial Identification

The emergence of goose astrovirus (GAstV) as a significant pathogen of domestic waterfowl represents a notable chapter in the history of emerging avian viral diseases. Although astroviruses have been recognized in avian species for decades, the pathogenic potential of GAstV was not fully appreciated until the winter of 2016–2017, when a severe, previously uncharacterized disease characterized by visceral and articular gout erupted in goslings across major goose-producing regions of China [38, 39]. Initial investigations identified the causative agent as a novel, divergent astrovirus, designated initially as strains such as AStV-SDPY and GD, which exhibited less than 60.8% nucleotide homology with other known astroviruses in GenBank, confirming its status as a distinct and emerging pathogen [38, 39]. This seminal identification was the culmination of systematic virological and pathological investigations that ruled out other known agents of avian gout and nephritis, pinpointing the novel GAstV as the primary etiological agent [38, 39, 59]. The rapid recognition of this virus was critical, as the disease spread with alarming speed, transforming from a localized outbreak into a nationwide epizootic within a few years.

Spatiotemporal Dynamics and Geographic Expansion in China

Since its initial recognition, GAstV has undergone a dramatic geographic expansion, establishing itself as an endemic pathogen in virtually all major goose-producing provinces of China. Comprehensive epidemiological surveillance and phylogeographic analyses have meticulously mapped this spread. Initial outbreaks were concentrated in eastern coastal provinces such as Shandong and Jiangsu, but the virus has since disseminated extensively, with documented circulation in at least 17 provinces over the past decade [3]. By December 2022, infections had been confirmed in Jiangsu, Shandong, Anhui, Henan, Guangdong, Liaoning, Sichuan, and numerous other regions [54]. Phylogeographic modeling, based on 90 reported cases from 13 provinces, revealed the complexity and severity of the epidemic, identifying Henan, Anhui, and Jiangsu provinces as having suffered particularly severe impacts [28]. This analysis traced the initial introduction of GAstV likely from Hunan Province, followed by a nationwide dispersal pattern that strongly correlates with the live gosling trade, a common practice in Chinese agriculture that facilitates the rapid translocation of infected birds across vast distances [28]. The economic toll of this epizootic has been staggering, with losses from GAstV infection in the Chinese goose industry estimated to exceed tens of billions of yuan [15]. The high morbidity and mortality rates, often ranging from 10% to 60% in affected flocks [5] and reaching up to 50% in many outbreaks [22, 24], have rendered this disease the single most important infectious threat to the Chinese goose industry.

Genetic Diversity, Genotypic Classification, and Molecular Epidemiology

The molecular epidemiological landscape of GAstV is defined by a dynamic and evolving population structure, driven by recombination, mutation, and selective pressure. Genomic analyses have unequivocally classified GAstV into two major genotypic species: GAstV-I (GI) and GAstV-II (GII) [3, 25, 29]. This bipartite classification is robustly supported by whole-genome phylogenetic analysis, which further divides these groups into six distinct subgroups, reflecting significant genetic divergence [3]. The evolutionary history of these genotypes is distinct; Bayesian coalescent analyses estimate that GAstV-I emerged much earlier, around April 1985, while GAstV-II emerged more recently, estimated to have occurred around January 2010 [29]. Crucially, GAstV-II has been identified as the predominant and most pathogenic genotype responsible for the widespread gout epizootics since its emergence [11, 25, 42]. Within GAstV-II, a specific subgenotype, IId, has risen to become the dominant circulating strain across China, succeeding earlier subgroups like II-c [19, 25, 42].

The drivers of this genetic diversity are multifaceted. Recombination is a powerful force in GAstV evolution, with studies identifying up to 27 distinct recombination events across the genome, particularly within the GAstV-II subgenotypes [3, 25, 60]. These recombination events can involve both inter-genotypic (between GAstV-I and GAstV-II) and intra-genotypic exchanges, as well as recombination with other avian astroviruses like turkey astrovirus [17, 60]. Codon usage bias analyses have provided insights into host adaptation, revealing that GAstV-II exhibits a weaker codon usage bias compared to GAstV-I, which may confer greater translational flexibility and enhance its adaptability across different host environments [11]. Furthermore, the structural protein of GAstV-II, particularly the spike protein, demonstrates significantly lower variability than that of GAstV-I, as determined by Shannon entropy analysis [11]. This structural stability may reduce the frequency of antigenic drift required for persistence, contributing to the sustained transmission and dominance of GAstV-II in the field [11]. The identification of specific amino acid mutations, such as characteristic deletions at positions 652-653 and 706 in the capsid protein serving as markers for GI a and GI b subgroups [3], and the E456D, A464N, and L540Q mutations in GAstV-II d strains [19], provides molecular tools for tracking epidemic strains.

Host Range and Cross-Species Transmission

A critical aspect of GAstV epidemiology is its expanding host range, moving beyond geese to infect other domestic poultry species. While GAstV is highly pathogenic for goslings, compelling evidence demonstrates its ability to cross the species barrier and cause disease in both ducks and chickens. The infection of ducks is now well-documented. Outbreaks of visceral gout in Cherry Valley ducklings in Shandong Province in 2019 [35] and in Muscovy ducklings in Henan Province in 2020 [31] were confirmed to be caused by novel GAstV strains, with mortality rates reaching 30% and 61%, respectively. Phylogenetic analysis of these duck-origin strains, such as SDXT and HNNY0620, showed they clustered within the GAstV branches, confirming that the virus can effectively jump from geese to ducks [35, 37]. Further surveillance in Guangdong Province from 2023-2024 identified GAstV as the primary pathogen in 43.65% of duck liver samples from farms reporting emaciation, paralysis, and death, representing the first report of GAstV causing severe symptoms and mortality in Muscovy ducks in that province [12]. These findings suggest that ducks may serve as key amplifying hosts, underscoring the risk of cross-species transmission within the waterfowl industry [12].

The host range also extends to chickens. Experimental infection of specific-pathogen-free (SPF) White Leghorn chickens with GAstV-2 resulted in depression, anorexia, diarrhea, weight loss, extensive organ damage, and high viral loads in tissues, confirming that chickens are susceptible and can shed the virus, posing a risk to other landfowl [20]. Moreover, a GAstV-2 strain (GoAstV-SDHZ) was isolated for the first time from laying hens presenting with nephritis in Shandong Province [57], providing direct field evidence of natural infection in chickens. These combined data indicate that GAstV is not a pathogen restricted to geese but is an emerging multi-host pathogen with the potential to infect a wide range of commercial poultry. Host adaptation analysis of codon usage bias further supports the suitability of both geese and ducks as hosts for the virus [13].

Global Distribution and Threat to International Poultry Industries

To date, the occurrence of GAstV-associated gout disease has been overwhelmingly reported within China, where it has become endemic [22, 24]. No confirmed outbreaks of the severe gout pathology caused by GAstV have been reported in other major goose-producing regions of the world, such as Europe. However, the potential for global dissemination is a legitimate and pressing concern for international veterinary authorities, including the World Organisation for Animal Health (WOAH). The virus is considered an emerging threat with probable worldwide impact if introduced into naive populations [22]. The primary risks for international spread are multifaceted: the global trade in live poultry and poultry products, the potential for contaminated fomites (equipment, vehicles, clothing), and the inherent infectivity and environmental stability of astroviruses. The ability of the virus to infect multiple avian species, including chickens and ducks, further amplifies the risk, as these species are traded globally in vastly higher numbers than geese. The presence of GAstV in hatcheries and evidence of vertical transmission [30, 58] compound this risk, as contaminated eggs or day-old chicks could serve as a silent conduit for introduction into new geographic regions. Therefore, GAstV should be considered a notifiable pathogen of high priority for surveillance and biosecurity planning by poultry health authorities and international bodies like the Food and Agriculture Organization (FAO) and WOAH.

Clinical Signs, Pathology, and Diagnostic Detection of GAstV

Clinical Manifestations of Goose Astrovirus Infection

The clinical presentation of goose astrovirus (GAstV) infection is predominantly defined by a biphasic disease course that reflects the genotype-specific tropism and pathogenic mechanisms of the virus. Since the initial emergence of GAstV-associated gout disease in China in 2015-2016, two distinct clinical syndromes have been recognized, corresponding to infection with GAstV genotype 1 (GAstV-I) and genotype 2 (GAstV-II) [1, 39]. The clinical signs exhibit remarkable variation in severity, mortality, and organ system involvement, necessitating a nuanced understanding for accurate field diagnosis and epidemiological surveillance.

GAstV-II Infection: The Gout Syndrome

GAstV-II, which has become the predominant circulating genotype since 2017, is responsible for the most severe clinical manifestations, a fulminant visceral and articular gout syndrome that typically affects goslings between 3 and 20 days of age [10, 22]. The incubation period is remarkably short, with clinical signs appearing as early as 48 hours post-infection under experimental conditions, and mortality peaking within 5-7 days [65, 69]. Affected goslings initially present with nonspecific signs including depression, anorexia, polydipsia, and progressive lethargy. As the disease advances, a characteristic constellation of symptoms emerges: white, chalky urate deposits become visible on the visceral organs and within the joint cavities [17, 24]. The tarsal and toe joints become swollen and painful, leading to lameness and an inability to stand or ambulate [42]. Clinicians should note that the term "villous heart" has been employed to describe the dramatic appearance of urate crystals coating the epicardial surface, a pathognomonic finding in severe cases [42].

The mortality rate associated with GAstV-II infection is alarmingly high, ranging from 10% to 60% in natural outbreaks, with some virulent strains achieving mortality rates of 80-93% under experimental conditions [4, 17, 63]. A critical observation reported by Xu et al. (2024) documented that the GAstV SCG3 strain induced 93.1% mortality in goslings and 80% mortality in goose embryos, representing the first report of a GAstV strain with such extreme virulence [63]. This mortality is typically observed within 5-10 days post-infection, with death often preceded by severe hyperuricemia and renal failure [16, 55]. Importantly, surviving goslings frequently exhibit stunted growth, reduced weight gain, and persistent weakness, contributing to significant economic losses beyond acute mortality [4, 65].

GAstV-I Infection: The Enteric Syndrome

In contrast to the predominant gout phenotype associated with GAstV-II, GAstV-I infection presents a fundamentally different clinical picture that has only recently been characterized. Initial reports suggested that GAstV-I was also capable of causing gout; however, more rigorous experimental studies have demonstrated that GAstV-I primarily induces an enteric disease syndrome. Wang et al. (2025) reported that experimental infection of one-day-old goslings with the GAstV-1 strain JY202323 resulted in diarrhea and weight loss with a mortality rate of approximately 13%, yet critically, no typical gout symptoms were observed [4]. Similarly, Chen et al. (2025) isolated a GAstV-1 strain from Sichuan Province that caused severe intestinal damage characterized by necrosis, inflammatory infiltration, and crypt architectural disruption, with a mortality rate of approximately 30% [5]. These findings challenge earlier assumptions about the pathogenicity of GAstV-I and underscore the importance of genotype-specific diagnostic approaches.

The clinical distinction between GAstV-I and GAstV-II infections has profound implications for disease management and biosecurity protocols. GAstV-I infection should be suspected in outbreaks characterized by enteritis, diarrhea, and moderate mortality without the dramatic urate deposition typical of GAstV-II [4, 5]. Conversely, the presence of visceral and articular gout, particularly in goslings under three weeks of age, is highly suggestive of GAstV-II infection, though mixed infections with both genotypes are increasingly recognized [7, 18].

Cross-Species Transmission and Host Range

The host range of GAstV extends beyond geese, representing a significant concern for the global poultry industry. Experimental and field evidence has demonstrated that GAstV can infect chickens, ducks, and Muscovy ducks, producing clinical disease and mortality [12, 20, 31, 34, 35]. He et al. (2023) demonstrated that GAstV-2 infection in specific pathogen-free (SPF) chickens resulted in depression, anorexia, diarrhea, weight loss, extensive organ damage, and high viral loads in tissues, with subsequent viral shedding posing a transmission risk to other poultry [20]. Remarkably, outbreaks of GAstV have been documented in adult Landaise geese, challenging the conventional wisdom that the disease is restricted to young goslings [67]. The isolation of GAstV from laying hens with nephritis in Shandong Province further expands the host range and raises concerns about the potential for GAstV to establish endemicity in mixed poultry operations [57]. The World Organisation for Animal Health (WOAH) should consider GAstV as an emerging transboundary pathogen with significant economic implications for the global waterfowl industry, particularly given the expanding geographic distribution of the virus across 17 provinces in China [3].

Pathological Findings and Pathogenesis

The pathology of GAstV infection is characterized by a complex interplay of direct viral cytopathology, immune-mediated tissue damage, and metabolic dysregulation that collectively produce the hallmark lesions of urate deposition and organ failure. A comprehensive understanding of these pathological processes is essential for accurate diagnosis and the development of targeted therapeutic interventions.

Gross Pathology: The Signature of Urate Deposition

At necropsy, GAstV-II-infected goslings present a striking and unmistakable appearance. The most conspicuous finding is the widespread deposition of white, chalky urate crystals on the surfaces of visceral organs, including the heart, liver, spleen, kidneys, and the serosal surfaces of the gastrointestinal tract [17, 24]. The kidneys are typically pale, swollen, and hemorrhagic, with urate deposits visible in the renal parenchyma and collecting system [39, 42]. In severe cases, the ureters are distended with urate casts, and the joint cavities, particularly the hock and stifle joints, contain accumulations of urate-laden fluid [16, 42]. The liver may appear mottled with pale foci of necrosis, and the spleen is often enlarged and congested [17, 18]. A particularly notable finding is the "villous heart," where the epicardial surface is coated with a thick layer of urate crystals, giving the heart a shaggy, hairy appearance [42].

In contrast, GAstV-I infection produces a distinct gross pathological picture. The predominant findings include intestinal congestion, hemorrhagic enteritis, and mesenteric edema, with minimal to absent urate deposition [4, 5]. The liver and spleen may show necrosis, but the dramatic urate accumulation characteristic of GAstV-II is notably absent [5, 14].

Histopathology: Cellular and Tissue-Level Damage

Histological examination reveals the extent and severity of GAstV-induced tissue damage. The kidney is the primary target organ for GAstV-II, with lesions characterized by severe tubular necrosis, interstitial nephritis, and the presence of urate tophi within the renal tubules and interstitium [16, 55, 66]. Renal tubular epithelial cells exhibit degenerative changes, including swelling, vacuolation, and desquamation into the tubular lumen [65]. Immunohistochemical studies have demonstrated that GAstV-2 antigens are predominantly localized in the cytoplasm of renal tubular epithelial cells, with staining intensity correlating with the severity of lesions [66]. The renal interstitium is infiltrated by lymphocytes, macrophages, and heterophils, indicative of an active inflammatory response [16, 18]. Masson trichrome and Picrosirius Red staining have revealed significant renal fibrosis in chronic cases, suggesting that GAstV infection can induce irreversible structural damage [16].

The liver exhibits centrilobular necrosis, hepatocyte swelling, and inflammatory cell infiltration [51, 61]. Electron microscopy has demonstrated dilation of the endoplasmic reticulum and chromatin margination, features consistent with endoplasmic reticulum stress and apoptosis [51]. Biochemical analyses have confirmed significant elevations in serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT), reflecting substantial hepatocellular injury [51, 67]. Importantly, Yin et al. (2025) demonstrated that GAstV infection disrupts hepatic lipid metabolism, leading to lipid deposition in hepatocytes, as confirmed by Oil Red O staining and alterations in PPAR signaling pathway genes [61].

The spleen shows lymphoid depletion, particularly in the white pulp, and the presence of urate tophi [18, 65]. The bursa of Fabricius, a primary lymphoid organ in birds, exhibits follicle atrophy and lymphocyte depletion, suggesting that GAstV may induce immunosuppression [14]. In the intestine, particularly the duodenum and jejunum, GAstV-I infection causes villous atrophy, crypt necrosis, and inflammatory cell infiltration [4, 5, 10]. Li et al. (2025) reported that GAstV-2 infection caused intestinal injury characterized by crypt necrosis, shortened villus height, reduced numbers of Lgr5+ stem cells, and increased expression of inflammatory cytokines, while the host responded by increasing Paneth cell numbers and upregulating tight junction proteins [10].

Pathogenesis: The Molecular Basis of Gout Formation

The pathogenesis of GAstV-induced gout is multifactorial, involving both increased uric acid production and decreased renal excretion. Uric acid is the end product of purine metabolism in birds, and its homeostasis is maintained through the balance of hepatic production and renal clearance. Wu et al. (2020) demonstrated that GAstV infection increases the activity and mRNA expression of xanthine dehydrogenase (XOD) and adenosine deaminase (ADA) in the liver, key enzymes in the purine degradation pathway that generate uric acid [55]. Concurrently, renal excretion of uric acid is impaired, as evidenced by decreased mRNA expression of multidrug resistance-associated protein 4 (MRP4) and reduced Na-K-ATPase activity in the kidneys [55].

The role of adenosine deaminase (ADA) in GAstV pathogenesis has been further elucidated by Zhai et al. (2025), who demonstrated that GAstV-II infection promotes ADA production in goose embryo fibroblasts (GEFs), and that ADA interacts directly with the viral capsid protein, particularly its C-terminal domain [43]. Ectopic expression of ADA significantly enhances viral capsid protein expression and virus loads, while siRNA-mediated knockdown of ADA inhibits viral replication, suggesting that ADA serves as a proviral factor that facilitates GAstV replication [43, 45].

Inflammatory and immune mechanisms play a central role in GAstV pathogenesis. The virus activates pattern recognition receptors including RIG-I, MDA5, and TLR3, leading to the upregulation of proinflammatory cytokines such as IL-1β, IL-6, IL-8, and TNF-α [16, 48, 54]. The NLRP3 inflammasome pathway is activated in GAstV-infected goose embryonic kidney cells, resulting in increased production of IL-1β and contributing to the inflammatory milieu [48]. Apoptosis is a prominent feature of GAstV infection, with infected cells exhibiting increased expression of pro-apoptotic proteins (Bax, caspase-3, caspase-9, cytochrome c) and decreased expression of the anti-apoptotic protein Bcl-2 [48, 51]. Endoplasmic reticulum stress (ERS) has been identified as a critical upstream event in GAstV-induced apoptosis, with infection leading to activation of the PERK, IRE1α, and ATF6 pathways [51].

The gut microbiome has emerged as a significant contributor to GAstV pathogenesis. Li et al. (2024) demonstrated that GAstV infection significantly alters the gut microbiome of goslings, with enrichment of potential proinflammatory bacteria and depletion of beneficial bacteria that produce short-chain fatty acids [47]. Critically, the microbial pathway involved in urate production was significantly increased in infected goslings, suggesting that gut microbiome-derived urate may contribute to the development of gout symptoms, independent of viral-induced organ damage [47].

Immunosuppression is a notable consequence of GAstV infection. Ding et al. (2024) demonstrated that GAstV-2 can infect both CD4+ and CD8+ T lymphocytes and macrophages, reducing lymphocyte proliferation induced by mitogens and increasing lymphocyte apoptosis [53]. This immunosuppression may predispose infected goslings to secondary infections and contribute to the high mortality observed in field outbreaks.

Diagnostic Detection of GAstV

The accurate and timely detection of GAstV is paramount for implementing effective control measures, conducting epidemiological surveillance, and understanding the molecular epidemiology of this emerging pathogen. A comprehensive diagnostic armamentarium has been developed, ranging from rapid point-of-care tests to highly sensitive molecular and serological assays.

Molecular Detection Methods

Reverse transcription polymerase chain reaction (RT-PCR) and its real-time quantitative variant (RT-qPCR) represent the gold standard for GAstV detection due to their high sensitivity, specificity, and rapid turnaround time. The conserved ORF1b gene has been the preferred target for assay development, as it exhibits high sequence conservation across GAstV genotypes and allows for universal detection [6, 62, 68]. Wang et al. (2022) developed a duplex rRT-PCR assay targeting the ORF1b gene that achieved a detection limit of 10 copies/reaction for both GAstV-1 and GAstV-2, with no cross-reactivity against 10 other common waterfowl pathogens [68]. Liu et al. (2025) subsequently developed a dual RT-qPCR assay with detection limits of 1.0 × 10² copies/reaction for both genotypes, demonstrating amplification efficiencies of 96.06% for GAstV-1 and 90.39% for GAstV-2, with coefficients of variation below 3% [6].

Genotype-specific differentiation is critical for epidemiological studies and understanding the differential pathogenicity of GAstV-I and GAstV-II. Li et al. (2023) developed a TaqMan-based duplex real-time quantitative PCR that achieved detection limits of 100 copies/μL for GAstV-1 and 10 copies/μL for GAstV-2, with no false positives for other common avian viruses [64]. Similarly, Yi et al. (2022) developed a duplex TaqMan RT-qPCR assay targeting the ORF2 gene with detection limits of 33.3 and 33.7 DNA copies/μL for GAstV-1 and GAstV-2, respectively [27]. Clinical application of these assays has revealed complex co-infection patterns, with GAstV-2 being the predominant genotype and mixed infections detected in a substantial proportion of clinical samples [6, 7, 27, 64].

Droplet digital PCR (ddPCR) represents a significant advancement in GAstV detection, offering absolute quantification without the need for standard curves. Shi et al. (2024) developed a ddPCR assay targeting the conserved region of the ORF2 gene that achieved a detection limit of 10 copies/μL, approximately 28 times more

Genetic Evolution and Phylogenetic Diversity of GAstV

The evolutionary trajectory and phylogenetic architecture of goose astrovirus (GAstV) represent a compelling narrative of a pathogen that has undergone rapid molecular diversification and geographic expansion, transitioning from an obscure avian enteric virus to a dominant etiological agent of systemic gout disease in waterfowl. Since its initial recognition as a causative agent of gosling gout in 2016, GAstV has been subjected to intense genomic surveillance, yielding a dataset of complete genome sequences that now exceeds 180 isolates [1, 3, 22]. This wealth of molecular data has fundamentally reshaped our understanding of astrovirus evolution within the avian host, revealing that GAstV exists not as a monolithic entity but as a genetically heterogeneous viral population shaped by recombination, host selection pressures, and punctuated substitution events.

Genotypic Classification and Phylogenetic Framework

The foundational phylogenetic framework for GAstV is predicated on whole-genome and open reading frame (ORF)-based analyses, which have consistently resolved two major genotypic clusters: GAstV-I (genotype 1) and GAstV-II (genotype 2) [3, 18, 22, 25]. This bipartite classification, first formally articulated through comprehensive phylogenetic reconstructions of complete genomes by Li and colleagues in 2025, is supported by deep genetic distances between the two groups, with ORF2 (capsid) amino acid sequence identities as low as 42.5% between representative strains [18]. Such divergence is not merely a statistical artefact but reflects fundamentally distinct evolutionary histories, with GAstV-I showing closer phylogenetic affinity to duck astrovirus type IV (DAstV-IV) and certain turkey astrovirus lineages, whereas GAstV-II clusters more robustly with DAstV-II and turkey astrovirus type II [28, 31].

Importantly, the phylogenetic signal derived from different genomic regions is not uniformly concordant. Analysis of the ORF1a and ORF1b regions, which encode the non-structural polyproteins including the serine protease and RNA-dependent RNA polymerase (RdRp), respectively, often yields different topologies compared to the ORF2 capsid gene [25]. This incongruence is a hallmark of recombination-driven evolution, where individual genomic segments carry distinct phylogenetic signatures due to past exchange events. The International Committee on Taxonomy of Viruses (ICTV) has not yet formally assigned GAstV genotypes at the species level, but the preponderance of evidence supports the classification of GAstV-II within the Avastrovirus 3 species, while GAstV-I aligns with Avastrovirus 1 [29, 34]. This taxonomic positioning underscores the remarkable diversity within what is colloquially termed "goose astrovirus," a nomenclature that belies the genetic complexity of these viruses.

Subgenotypic Complexity and Geographic Dissemination

Within the two major genotypic clusters, further phylogenetic stratification has been consistently observed, revealing a dynamic subgenotypic landscape that has evolved rapidly over the past decade. Li et al. (2025), utilizing 183 complete genome sequences, identified six distinct subgenotypes within the GAstV-I and GAstV-II lineages [3]. For GAstV-I, two major subgroups, designated GI-a and GI-b, have been characterized, with GI-a further divisible into distinct clades based on capsid protein sequence variability [4, 14, 26]. The GAstV-I subgroup GI-b, represented by strains such as FLX and TZ03, demonstrates geographically widespread distribution across eastern China, including Jiangsu, Shandong, and Jiangxi provinces [4, 14, 23, 26].

The subgenotypic diversity of GAstV-II is considerably more complex, with at least four subgroups (GII-a, GII-b, GII-c, and GII-d) identified through rigorous phylogenetic analysis [3, 19, 25, 28]. The GII-d subgroup, first recognized in the late 2010s, has undergone rapid expansion and now constitutes the dominant circulating lineage in most major goose-producing regions of China, including Shandong, Henan, Anhui, Jiangsu, and Guangdong provinces [19, 42]. This lineage replacement, from earlier GII-a and GII-b strains to the currently predominant GII-d, is reminiscent of antigenic drift dynamics observed in other RNA viruses and suggests a selective advantage for the GII-d lineage, potentially related to enhanced replicative fitness, immune evasion, or altered tissue tropism.

Spatiotemporal dynamic analyses based on phylogeographic reconstruction have traced the emergence and dissemination of GAstV across China with remarkable resolution. Bayesian inference methods applied to ORF2 sequences have estimated the time to the most recent common ancestor (TMRCA) for GAstV-II at approximately January 2010, with a mean evolutionary rate of 1.42–1.46 × 10⁻³ nucleotide substitutions per site per year [29, 34]. For GAstV-I, the TMRCA is considerably older, estimated at April 1985, suggesting that GAstV-I has circulated in waterfowl populations for decades prior to the emergence of GAstV-II as a clinically significant pathogen [29]. The initial introduction of GAstV-II into goose populations is hypothesized to have originated from Hunan Province, with subsequent dispersal driven by the live gosling trade and the movement of infected birds across provincial borders [28]. By 2024, the virus had been detected in at least 17 provinces, representing a geographic expansion unprecedented in avian astrovirus epidemiology [1, 3]. The phylogeographic patterns indicate that Henan, Anhui, and Jiangsu provinces have served as major epicenters for viral dissemination, with multiple introduction events and subsequent local circulation establishing complex transmission networks [28].

Recombination as a Primary Evolutionary Driver

Perhaps the most significant insight into GAstV evolution is the recognition that homologous recombination is a pervasive and potent mechanism driving genomic diversification. Systematic screening of complete genome sequences has identified a minimum of 27 recombination events across Chinese GAstV isolates, with the majority concentrated within GAstV-II strains [3, 25]. These recombination breakpoints are non-randomly distributed across the genome, with hot spots identified in the ORF1a/ORF1b junction region and within the ORF2 capsid gene [17, 25, 60]. The biological consequences of recombination are profound: genomic segments inherited from different parental lineages can be reassorted into novel combinations, potentially conferring altered antigenicity, tissue tropism, or replicative capacity.

Two specific recombination events illustrate the complexity of GAstV genomic mosaicism. Xu and colleagues (2024) characterized recombinant GAstV strains GXNN and GDCS, in which a recombination event was identified between the GAstV TZ03 strain and turkey astrovirus CA/00 in the 3' region of the genome, spanning nucleotides 6833–7070 [17]. The GDCS strain additionally carried a second recombinant interval in the 5' region, between GAstV XT1 and SDPY strains [17]. These inter-species and inter-genotypic recombination events highlight the capacity of GAstV to acquire genetic material from divergent astrovirus lineages, including those from turkey hosts, raising important questions about the ecological contexts in which such co-infections occur. The detection of recombination between GAstV and turkey astrovirus is particularly concerning, as it implies that waterfowl may serve as mixing vessels for avian astroviruses, facilitating the emergence of chimeric viruses with unpredictable biological properties.

The epidemiological evidence for mixed infections that could facilitate recombination is compelling. Co-infection rates between GAstV-I and GAstV-II in clinical samples from Guangdong Province have been reported as high as 50.4% (194/385 samples), indicating that individual animals are frequently infected with multiple genotypic lineages simultaneously [7]. Similarly, in Jiangxi Province, co-infection rates of 12.28–15.38% have been documented [6, 26, 27]. These data confirm that co-infection is not a rare event but a common feature of GAstV epidemiology, providing the ecological substrate for recombination to occur. The dual RT-qPCR and RPA assays developed for differential detection of GAstV-1 and GAstV-2 have been instrumental in revealing this hidden co-infection burden [6, 27, 62, 68].

Selective Pressures and Codon Usage Bias

The evolutionary dynamics of GAstV are shaped by the interplay between mutational input, selective constraints, and population-level processes. Molecular adaptation analyses employing codon-based models of evolution have demonstrated that the GAstV genome is primarily under strong purifying (negative) selection, which acts to eliminate deleterious mutations and maintain functional integrity of viral proteins [25, 42]. However, specific amino acid sites within the capsid protein, particularly in the surface-exposed P2 domain, are subject to positive (diversifying) selection, indicating ongoing adaptive evolution in regions that interact with host immune receptors or cellular entry factors [25].

The analysis of codon usage bias (CUB) has provided additional insights into GAstV host adaptation. Man and colleagues (2025) conducted a comprehensive assessment of CUB across 179 GAstV-II coding sequences derived from geese, ducks, chickens, and Muscovy ducks, revealing that the GAstV genome exhibits a relatively low codon usage bias, with effective number of codons (ENC) values exceeding 50 [13]. This weak bias is characteristic of viruses that have recently emerged or are undergoing host range expansion, as they have not yet optimized their codon usage to match the host translational machinery. Notably, natural selection, rather than mutation pressure, was identified as the dominant force shaping CUB in GAstV [13]. The ORF1a non-structural protein exhibited the highest degree of host adaptation, with the lowest similarity index (SiD) values relative to the goose genome, suggesting that the non-structural proteins play a critical role in facilitating viral replication within the host cellular environment [13].

Comparative CUB analysis between GAstV-II and GAstV-I revealed significant differences. Jiang et al. (2025) demonstrated that GAstV-II exhibits a weaker codon usage bias relative to GAstV-I, implying greater flexibility in synonymous codon usage and potentially enhanced adaptability across diverse host environments [11]. This finding is consistent with the epidemiological observation that GAstV-II has become the dominant genotype in China since 2017, while GAstV-I, despite its earlier emergence, remains less prevalent. The lower codon adaptation index (CAI) values of GAstV-II relative to the goose host further suggest that GAstV-II may experience reduced competition with host tRNA pools, thereby facilitating more efficient viral protein synthesis and replication [11].

Structural and Functional Implications of Capsid Diversity

The capsid protein (encoded by ORF2) is the primary determinant of antigenicity, host receptor binding, and viral assembly, and it is the most variable region of the GAstV genome. Comparative analysis of capsid amino acid sequences has identified 210 specific variation sites across GAstV strains, with characteristic deletions at positions 652–653 and 706 serving as reliable molecular markers for the GI-a and GI-b subgroups, respectively [3]. Within GAstV-II, several signature mutations have been associated with subgenotype emergence. The E456D substitution in the capsid spike domain is a hallmark of the GII-d lineage, and additional mutations including A464N and L540Q have been identified in later isolates, suggesting a stepwise accumulation of amino acid changes over time [19, 28, 69]. The L540Q mutation in the spike domain has been shown to affect protein structure prediction, potentially altering the conformation of surface-exposed loops involved in receptor interactions [69].

Structural modeling using AlphaFold 2.0 has provided detailed insights into the conformational differences between GAstV-I and GAstV-II capsid proteins. Liu and colleagues (2025) compared the VP34 (core) and VP27 (spike) structural proteins of GAstV-I strain GDYJ and GAstV-II strain GDZJ, revealing critical differences in the VP34 protein: an α-helix in the S223-A226 region of GAstV-II was replaced by a loop structure in the Q235-Q237 region of GAstV-I [7]. The VP27 spike proteins of both subtypes, while retaining five β-sheet structures, exhibited remarkably low sequence similarity of only 37.1%, highlighting the profound structural divergence in the region responsible for host cell attachment and antibody neutralization [7].

These structural differences have direct implications for antigenic diversity. Epitope mapping studies have identified linear B-cell epitopes that are highly conserved within genotypic groups but divergent between them. For GAstV-II, the epitope ¹⁵³NTAGPESIDT¹⁶² in the capsid protein is conserved among GAstV-2 strains but shares only 90% similarity with turkey astrovirus 2 and less than 50% with other astroviruses [2]. Similarly, the epitopes ¹MADRA⁵ and ³⁶YKPQKLPMKA⁴⁵ are conserved GAstV-2-specific epitopes within the S domain, while the GAstV-1-specific epitope ³⁹⁴SNREVQITQL⁴⁰³ resides in the P1 domain and shows marked divergence from GAstV-2 and other avian astroviruses [8, 9]. The neutralizing epitopes ⁴⁴³ESCSFLVF⁴⁵⁰ and ⁴²⁵QVTPSLVYNF⁴³⁴, located in the P2 domain of GAstV-2, are highly conserved among GAstV-2 strains but exhibit substantial divergence from GAstV-1, providing potential targets for epitope-based vaccine design [40].

Temporal Dynamics and Effective Population Size

The population dynamics of GAstV-II have been characterized by a rapid expansion phase followed by population stabilization. Phylogenetic and effective population size analyses, using coalescent-based approaches, revealed that GAstV-II underwent a pronounced demographic expansion between 2017 and 2018, coincident with the widespread emergence of gosling gout outbreaks across China [11]. This expansion was likely driven by the introduction of the virus into naïve goose populations, where transmission was unimpeded by pre-existing immunity. Following this initial expansion, the effective population size stabilized, suggesting that the virus has reached an equilibrium state within the host population, with ongoing transmission maintained by constant circulation among susceptible goslings [11].

The Shannon entropy analysis of the spike protein further revealed that GAstV-II exhibits significantly lower amino acid variability compared to GAstV-I, indicating greater structural stability of the capsid protein [11]. This reduced variability may diminish the requirement for frequent antigenic change, allowing GAstV-II to persist in host populations without undergoing constant evolution. Consequently, the lower antigenic variability likely decreases immune-driven selective pressure, contributing to the sustained viral transmission and long-term persistence observed in Chinese goose flocks.

The evolutionary history of GAstV, as reconstructed through Bayesian skyline plots and molecular clock analyses, indicates that the virus has been circulating in Chinese waterfowl for considerably longer than previously appreciated. The emergence of GAstV-II in geese around 2010, and the subsequent detection of GAstV-I as early as 1985, suggests that these viruses have been part of the avian virome for decades, possibly maintained in subclinical circulation or within reservoir host populations [29, 34]. The abrupt transition to clinical disease in 2015–2016 likely resulted from a combination of factors, including viral genetic changes that enhanced pathogenicity, increasing density of goose farming operations, and the introduction of highly susceptible goose breeds into endemic regions. Understanding this temporal framework is essential for predicting future emergence events and for designing surveillance strategies that can detect evolutionary changes before they translate into clinical outbreaks.

Structural Biology and Antigenicity of the GAstV Capsid Protein

The capsid protein (Cap) of goose astrovirus (GAstV), encoded by open reading frame 2 (ORF2), represents the sole structural component of the virion and is the primary determinant of viral antigenicity, host cell receptor recognition, and immunogenicity. As a non-enveloped, single-stranded positive-sense RNA virus within the family Astroviridae, genus Avastrovirus, GAstV relies entirely on this multifunctional protein for assembly, proteolytic maturation, and elicitation of protective host immune responses. The structural biology of the GAstV capsid is characterized by a complex hierarchical organization, extensive proteolytic processing, and a high degree of genetic variability that underpins the antigenic diversity between genotypes and drives viral evolution. Understanding these molecular features at an atomic level is critical for rational vaccine design, the development of specific diagnostic reagents, and elucidating the pathogenic mechanisms of gout disease in goslings.

Genomic Organization and Primary Structure of the Capsid Protein

The ORF2 gene of GAstV encodes a precursor capsid protein, typically referred to as VP90, with a predicted molecular mass of approximately 90 kDa [1, 22]. The complete genome of GAstV ranges from approximately 7,166 to 7,299 nucleotides in length, with ORF2 situated at the 3' end of the genome, downstream of ORF1a and ORF1b, which encode the non-structural polyproteins [4, 14, 17]. Sequence analysis of diverse GAstV strains has revealed that the capsid protein exhibits a modular architecture, comprising three major domains: a conserved N-terminal core domain (S domain), a central hypervariable domain (P1 domain), and a C-terminal spike domain (P2 domain) [2, 9, 56]. The S domain is responsible for the formation of the inner shell of the icosahedral capsid, while the P1 and P2 domains project outward and are involved in host cell attachment, receptor binding, and immune recognition. The full-length VP90 precursor undergoes a series of co- and post-translational cleavages mediated by host cell proteases, a process essential for capsid maturation and the acquisition of infectivity. Studies utilizing baculovirus expression systems have demonstrated that the full-length ORF2 protein is cleaved into mature fragments of approximately 40/43 kDa (core) and 25/27 kDa (spike), corresponding to the VP34 and VP27 proteins, respectively, which are the functional subunits of the mature virion [46, 71]. This proteolytic maturation is a hallmark of astrovirus biology and is critical for exposing receptor-binding sites and stabilizing the capsid architecture.

Three-Dimensional Architecture and Domain Organization

Structural predictions using advanced computational tools such as AlphaFold 2.0 have provided significant insights into the three-dimensional organization of the GAstV capsid protein, revealing distinct structural features that differentiate the two major genotypes, GAstV-I and GAstV-II [7, 17]. The VP34 core domain adopts a classic β-barrel fold, characteristic of the capsid proteins of many small RNA viruses, and forms the continuous icosahedral shell that encapsulates the viral genome. In contrast, the VP27 spike domain is composed primarily of β-sheet structures, forming a globular projection that extends from the capsid surface. A critical structural difference between the genotypes has been identified in the VP34 protein: GAstV-II strains possess a defined α-helix in the region spanning amino acids S223-A226, whereas GAstV-I strains exhibit a loop structure in the corresponding Q235-Q237 region [7]. This subtle conformational difference may influence capsid stability, assembly efficiency, or interactions with host factors. Furthermore, the VP27 spike domain, despite containing five β-sheet structures in both genotypes, displays remarkably low sequence similarity (approximately 37.1%) between GAstV-I and GAstV-II, underscoring the profound antigenic divergence between these two groups [7]. The P2 domain, which constitutes the outermost region of the spike, is of particular immunological importance. It is the primary target of neutralizing antibodies and contains the majority of B-cell epitopes identified to date [9, 40, 56]. Structural modeling has confirmed that the P2 domain is surface-exposed and adopts a β-sheet conformation, making it highly accessible to the host immune system [9].

Antigenic Variability and Epitope Mapping

The antigenic landscape of the GAstV capsid protein is characterized by a complex mosaic of linear and conformational B-cell epitopes, many of which are genotype-specific and subject to selective pressure. Comprehensive epitope mapping studies using monoclonal antibodies (mAbs) have identified a growing repertoire of antigenic sites distributed across the S, P1, and P2 domains. For GAstV-II, several linear epitopes have been precisely defined. A novel epitope, ¹⁵³NTAGPESIDT¹⁶², located within the N-terminal region of the capsid, was identified using mAb 7B2 and is highly conserved among GAstV-II strains, showing 90% similarity with turkey astrovirus 2 but less than 50% with other astroviruses, indicating its diagnostic potential for specific detection of GAstV-II [2]. Two additional epitopes, ¹MADRA⁵ and ³⁶YKPQKLPMKA⁴⁵, reside in the conserved S domain and are recognized by mAbs A12G1 and A10D12, respectively [8]. These S-domain epitopes are highly conserved among GAstV-II isolates but show notable divergence from GAstV-I, making them valuable for serotyping assays. Critically, two neutralizing epitopes have been identified within the P2 domain of GAstV-II: ⁴⁴³ESCSFLVF⁴⁵⁰ (recognized by mAb 4A7) and ⁴²⁵QVTPSLVYNF⁴³⁴ (recognized by mAb 8H3) [40]. These epitopes are surface-exposed and located in regions critical for virus-receptor interactions, and their identification provides direct targets for epitope-based vaccine design. For GAstV-I, a genotype-specific linear epitope, ³⁹⁴SNREVQITQL⁴⁰³, was identified within the P1 domain using the first GAstV-I-specific mAb, A5A1 [9]. This epitope is highly conserved among GAstV-I strains but markedly divergent from GAstV-II, enabling unambiguous differentiation between the two genotypes. Another epitope, spanning amino acids 627-646 in the ORF2 protein, has been successfully employed as the antigen in a peptide-based ELISA for serological surveillance of GAstV-I [33]. The identification of these epitopes has been instrumental in developing indirect competitive ELISAs (icELISAs) for detecting GAstV-specific antibodies in goose serum, providing robust tools for epidemiological monitoring and vaccine efficacy evaluation [8, 9, 32, 41].

Genetic Determinants of Antigenic Drift and Genotype Divergence

The capsid protein is the most variable region of the GAstV genome, and its genetic diversity is a primary driver of the emergence of distinct genotypes and subgenotypes. Large-scale genomic analyses of over 183 complete GAstV genomes have revealed that the capsid protein harbors 210 specific amino acid variation sites, with characteristic deletions at positions 652-653 and 706 serving as reliable molecular markers for the GI a and GI b subgroups [3]. Phylogenetic analysis of the ORF2 gene consistently divides GAstV into two major clades, GAstV-I and GAstV-II, with the amino acid sequence homology between the two genotypes being as low as 42.5% for the full-length ORF2 [18]. Within GAstV-II, further subdivision into subgenotypes (e.g., IIa, IIb, IIc, IId) has been documented, driven by specific mutations in the capsid protein. Key mutation sites, such as E456D, A464N, and L540Q in the P2 domain, are characteristic of the dominant GAstV-II IId subgenotype and have been associated with changes in viral fitness and prevalence [19, 28, 29]. The GAstV-II subgenotype IId has become the predominant circulating strain in China since 2017, and its success has been attributed, in part, to the structural stability of its spike protein. Shannon entropy analysis has demonstrated that the spike protein of GAstV-II exhibits significantly lower variability compared to GAstV-I, suggesting that a more stable antigenic structure reduces the need for frequent mutations to evade host immunity, thereby facilitating long-term persistence in host populations [11]. This lower antigenic variability likely decreases immune-driven selective pressure, allowing GAstV-II to maintain sustained transmission without undergoing constant antigenic evolution. In contrast, GAstV-I strains display greater capsid plasticity, which may contribute to their broader tissue tropism and the emergence of enteric versus gout-causing pathotypes [4, 5].

Post-Translational Modifications and Host Factor Interactions

The structural biology of the GAstV capsid extends beyond its primary sequence and fold to include critical interactions with host cellular proteins that modulate viral replication and pathogenesis. The capsid protein, particularly its C-terminal domain, has been shown to directly interact with host adenosine deaminase (ADA), an enzyme involved in purine metabolism and uricogenesis [43]. This interaction is functionally significant, as ADA promotes viral capsid protein expression and enhances virus loads in goose embryo fibroblast (GEF) cells, linking capsid biology to the metabolic dysregulation that underlies gout formation. Furthermore, the VP70 structural protein (a cleavage product of the capsid precursor) interacts with cellular vimentin (VIM), a key component of the intermediate filament network [49]. The interaction is mediated by amino acid residues 399-413 of VP70, and this binding induces the rearrangement of vimentin from a uniform cytoplasmic grid to a perinuclear aggregate, which co-localizes viral RNA and facilitates viral replication. Disruption of the VIM-VP70 interaction with acrylamide or site-directed mutagenesis significantly inhibits GAstV-2 replication, highlighting the essential role of this structural interaction in the viral life cycle. The capsid protein also plays a central role in modulating host innate immunity. The P2 domain of ORF2 is a potent inducer of 2'-5'-oligoadenylate synthetase-like (OASL) protein, a key antiviral effector of the interferon pathway [56]. This induction feeds back to restrict viral replication, revealing a host antiviral mechanism directly triggered by the capsid protein. Additionally, the capsid protein interacts with heat shock protein family A member 5 (HSPA5) on the surface of LMH cells, with docking predictions identifying seven key residues (THR124, ILE22, VAL24, TRP51, PRO66, GLN100, and VAL125) in the GAstV P2 protein that mediate this interaction, suggesting a potential role in viral entry [44].

Implications for Vaccine Design and Diagnostics

The detailed structural and antigenic characterization of the GAstV capsid protein has direct translational applications. The ability of the full-length ORF2 protein to self-assemble into virus-like particles (VLPs) when expressed in baculovirus systems provides a safe, non-infectious vaccine platform that mimics the native virion conformation [46]. These VLPs, approximately 30 nm in diameter, are highly immunogenic, inducing high levels of specific antibodies and a mixed Th1/Th2 immune response in goslings, with protection comparable to inactivated virus vaccines. The identification of genotype-specific linear B-cell epitopes has enabled the development of highly specific serological assays, including icELISAs and peptide-based ELISAs, which can differentiate between GAstV-I and GAstV-II infections [8, 9, 33]. Furthermore, the discovery of neutralizing epitopes within the P2 domain provides a rational basis for designing epitope-focused vaccines that elicit potent neutralizing antibody responses without including irrelevant or immunosuppressive regions of the capsid [40]. The structural stability of the GAstV-II spike protein, combined with its lower antigenic variability, suggests that vaccines based on this genotype may confer broad and durable protection against the dominant circulating strains. The development of mRNA vaccines encoding the full-length capsid protein, delivered via lipid nanoparticles, has also shown promise, eliciting robust humoral and cellular immune responses and significantly reducing viral shedding in challenged goslings [70]. Collectively, these advances underscore the centrality of capsid structural biology in the fight against GAstV, providing a molecular roadmap for the development of next-generation vaccines and diagnostic tools essential for controlling this economically devastating pathogen.

Current Control Strategies and Vaccine Development for GAstV

The emergence of goose astrovirus (GAstV) as a devastating pathogen of goslings, causing visceral and articular gout with mortality rates reaching up to 50% in affected flocks, has precipitated an urgent need for effective control strategies and vaccine development [1, 22, 24]. Since the initial identification of GAstV as the causative agent of gosling gout in 2016, the virus has spread extensively across 17 provinces in China, establishing itself as a persistent threat to the global waterfowl industry [1, 3, 22]. The World Organisation for Animal Health (WOAH) has recognized the economic significance of emerging astrovirus infections in poultry, and the Food and Agriculture Organization (FAO) has highlighted the need for improved surveillance and control measures for transboundary animal diseases affecting poultry production systems. Despite intensive research efforts, the development of commercially available vaccines and comprehensive control programs remains in its infancy, with no licensed products currently available for field use [1, 22, 70]. This section provides an exhaustive analysis of the current state of control strategies, including biosecurity measures, diagnostic surveillance, therapeutic interventions, and the multifaceted landscape of vaccine development against GAstV.

Biosecurity and Management-Based Control Strategies

In the absence of effective vaccines, biosecurity measures constitute the primary line of defense against GAstV introduction and spread within goose flocks. The virus demonstrates remarkable environmental stability, characteristic of non-enveloped astroviruses, and can persist in contaminated environments, feed, water, and equipment [22, 24]. Comprehensive biosecurity protocols must address multiple transmission routes, as GAstV is shed in high titers through feces and can be transmitted via the fecal-oral route, contaminated fomites, and potentially through vertical transmission [30, 58]. Ren et al. [30] provided compelling evidence for vertical transmission by detecting GAstV RNA in 2% of dead-in-shell embryos and day-old hatched goslings, indicating that hatchery contamination represents a critical control point. Furthermore, Zhang et al. [58] traced the source of GAstV outbreaks to goose hatcheries, isolating embryo-origin strains and demonstrating that vertical transmission from breeder flocks to progeny contributes significantly to disease dissemination.

The implementation of all-in-all-out production systems, strict quarantine protocols for newly introduced birds, and thorough disinfection of facilities between production cycles are essential components of an integrated biosecurity program [1, 22]. Given that GAstV-2 has become the dominant genotype circulating in China since 2017, with epidemiological surveys demonstrating its prevalence in 90.4% of gout-affected geese in Guangdong Province [7] and 66.35% of clinical samples testing positive for GAstV-2 [6], biosecurity measures must be particularly stringent in regions where this genotype is endemic. The virus's ability to infect multiple avian species, including chickens [20, 34], ducks [12, 31, 35, 37], and Muscovy ducks [12, 31], necessitates consideration of multi-species farming operations as potential reservoirs and transmission hubs. He et al. [20] demonstrated that GAstV-2 can infect specific-pathogen-free chickens, causing depression, anorexia, diarrhea, weight loss, and extensive organ damage, with infected chickens shedding virus and posing a potential risk to other domestic landfowl. This cross-species transmission capability, also documented in Cherry Valley ducklings [35] and Muscovy ducklings [31], underscores the importance of preventing contact between geese and other susceptible avian species on integrated poultry operations.

Diagnostic Surveillance as a Cornerstone of Control

Rapid and accurate detection of GAstV is fundamental to implementing effective control measures, enabling early identification of infected flocks, monitoring of viral circulation, and assessment of intervention efficacy. The development of a diverse array of diagnostic tools has been a major focus of GAstV research, with significant advances in molecular, serological, and point-of-care detection methods [1, 24]. Reverse transcription quantitative PCR (RT-qPCR) assays have been developed for genotype-specific detection, with duplex assays capable of simultaneously identifying and differentiating GAstV-1 and GAstV-2 achieving detection limits as low as 10 copies per reaction [68] and 33.3-33.7 copies per microliter [27]. Liu et al. [6] developed a dual RT-qPCR assay targeting the ORF1b gene with amplification efficiencies of 96.06% and 90.39% for GAstV-1 and GAstV-2, respectively, and demonstrated its utility in clinical samples where 18.27% were positive for GAstV-1 and 66.35% for GAstV-2, with 15.38% co-infected. These molecular tools provide the sensitivity and specificity necessary for accurate epidemiological surveillance and early outbreak detection.

For field-based applications where laboratory infrastructure is limited, isothermal amplification methods offer significant advantages in terms of speed, simplicity, and portability. Zheng and Zhang [74] developed a reverse transcription recombinase-aided amplification (RT-RAA) assay that achieves detection within 26 minutes at a constant temperature of 39°C, with a detection threshold of 1.19 × 10² copies per microliter and 100% agreement with pre-existing data in clinical sample validation. Similarly, Li et al. [77] established a real-time RT-RPA method for GAstV-2 detection that completes amplification in 25 minutes at 39°C, with a detection limit of 100 RNA copies per microliter and 99.6% positive concordance with RT-qPCR in 270 clinical samples. Liu et al. [62] advanced this technology further by developing a dual RT-qRPA assay capable of simultaneously detecting GAstV-1 and GAstV-2 within 20 minutes at 42°C, with detection limits of 109 and 86 copies per reaction, respectively, and 100% diagnostic concordance with RT-qPCR. The integration of CRISPR-Cas12a technology with isothermal amplification has pushed detection sensitivity to unprecedented levels, with Yang et al. [78] achieving a detection limit of 2 copies per reaction using reverse transcription-enzymatic recombinase amplification coupled with Cas12a detection, completing the entire procedure within one hour.

Nanobody-based lateral flow assays represent another innovative approach to rapid field detection. Wang et al. [73] developed colloidal gold immunochromatographic strips using nanobodies (Nb-58 and Nb-60) targeting the GAstV P2 protein, achieving a detection threshold of approximately 10¹·⁵⁷ TCID₅₀ with no cross-reactivity against other common avian pathogens, and demonstrating 100% and 95.24% coincidence rates with RT-PCR in clinical tissue and cloacal swab samples, respectively. The MIRA-LFD combination assay developed by Zhu et al. [76] enables multi-enzyme isothermal rapid amplification coupled with lateral flow dipstick detection, achieving a sensitivity of 1 copy per microliter within 15 minutes total detection time, with accuracy correlating well with RT-qPCR in clinical sample evaluation. These point-of-care diagnostic tools are invaluable for on-site surveillance, enabling rapid implementation of quarantine and control measures when GAstV is detected.

Serological surveillance provides complementary information on flock exposure history and immune status. Indirect ELISAs have been developed for genotype-specific antibody detection, with Zhang et al. [21] establishing assays using GAstV-1 virus and recombinant GAstV-2 capsid protein as coating antigens, achieving analytical sensitivities of 1:6400 and 1:3200, respectively, and demonstrating that GAstV-2 seroprevalence (71.4%) was substantially higher than GAstV-1 (33.3%) in field serum samples. Monoclonal antibody-based indirect competitive ELISAs offer enhanced specificity and reproducibility, with He et al. [32] developing an ic-ELISA showing 80% correlation with virus neutralization testing in field serum samples. Wang et al. [8] established an icELISA using mAb A10D12 against GAstV-2 ORF2, demonstrating excellent reproducibility, high sensitivity, and no cross-reactivity with antisera against other common waterfowl pathogens. Similarly, Wang et al. [9] developed a GAstV-1-specific icELISA using mAb A5A1, with a detection limit of 1:128 serum dilution, robust reproducibility with intra- and inter-assay CVs below 10%, and 87.5% concordance with immunofluorescence assay in clinical validation. Peptide-based ELISAs targeting specific B-cell epitopes offer advantages in terms of standardization and cost-effectiveness, with Ren et al. [33] developing a pELISA using a 627-646 aa peptide from ORF2 that demonstrated 87.5% concordance with IFA and excellent specificity for GAstV-1 antibody detection.

Therapeutic Interventions and Immunomodulatory Approaches

The development of effective therapeutic strategies for GAstV infection has been hampered by the lack of approved antiviral drugs and the limited understanding of viral pathogenesis. However, several promising approaches have emerged from recent research, including passive immunotherapy, immunomodulatory agents, and host-directed therapies. Xu et al. [75] demonstrated that chicken egg yolk immunoglobulin (IgY) produced from hens immunized with inactivated GAstV GDCS strain could effectively prevent and treat GAstV infection in goslings. The IgY, purified using polyethylene glycol precipitation, exhibited a neutralization titer of up to 2⁹·⁶⁷ in vitro and significantly reduced symptoms, mortality, tissue damage, and viral load when administered to goslings. This approach offers several advantages, including cost-effective production, oral administration可行性, and the absence of concerns regarding antibody-dependent enhancement or immunosuppression that can complicate mammalian antibody therapies.

The identification of host factors that modulate GAstV replication has opened new avenues for therapeutic intervention. Adenosine deaminase (ADA), an enzyme involved in purine metabolism and uricogenesis, was shown by Zhai et al. [43] to be upregulated during GAstV-II infection and to directly interact with the viral capsid protein, particularly its C-terminal domain. Ectopic expression of goose ADA significantly enhanced viral capsid protein expression and virus loads in goose embryo fibroblasts, while siRNA-mediated knockdown had the opposite effect. This suggests that targeting ADA or its interaction with the viral capsid protein could represent a novel antiviral strategy. Similarly, Li et al. [50] demonstrated that goose IFIT5, an interferon-induced protein, is upregulated during GAstV infection and conversely promotes viral replication, indicating that modulation of this host factor could influence infection outcome.

The role of nitric oxide (NO) in GAstV pathogenesis has been investigated as a potential therapeutic target. Zhu et al. [52] demonstrated that aminoguanidine, an inhibitor of inducible nitric oxide synthase (iNOS), significantly reduced mortality, serum uric acid and creatinine levels, and urate deposition in GAstV-2-infected goslings. Aminoguanidine treatment decreased renal tubular cell necrosis, inflammatory cell infiltration, and interstitial fibrosis, while reducing expression of renal injury markers and inflammatory cytokine-related genes. Importantly, aminoguanidine did not affect viral load in the kidney or liver, indicating that its therapeutic effect is mediated through modulation of host inflammatory and autophagic responses rather than direct antiviral activity. This finding highlights the potential of host-directed therapies that target pathogenic host responses rather than viral replication directly, potentially reducing the risk of drug resistance development.

The gut microbiome has emerged as a potential therapeutic target for GAstV-induced gout. Li et al. [47] demonstrated that GAstV infection significantly alters the gut microbiome of goslings, with enrichment of proinflammatory bacteria and depletion of beneficial short-chain fatty acid-producing bacteria. Importantly, the microbial pathway involved in urate production was significantly increased in infected goslings, suggesting that gut microbiome-derived urate may contribute to gout symptoms beyond the direct effects of viral-induced kidney damage. This finding opens the possibility of microbiome-based therapeutics, including probiotics, prebiotics, or fecal microbiota transplantation, as adjunctive treatments to reduce urate production and inflammation in GAstV-infected flocks.

Inactivated and Subunit Vaccine Development

The development of traditional inactivated vaccines against GAstV has been pursued as a straightforward approach to inducing protective immunity. Xu et al. [75] demonstrated that a GAstV GDCS strain inactivated with 1‰ formaldehyde at 37°C for 24 hours, emulsified with white oil adjuvant, could induce robust immune responses in laying hens, with IgY concentrations reaching 3.133 mg/mL after four immunizations. While this study focused on IgY production rather than direct vaccination of geese, it established the immunogenicity of inactivated GAstV antigens and provided proof-of-concept for inactivated vaccine approaches. However, the difficulty in efficiently culturing GAstV in vitro has hindered the development of traditional inactivated and live-attenuated vaccines, as the virus exhibits restricted cell tropism and requires adaptation to cell culture systems [46, 63].

Subunit vaccines based on recombinant capsid proteins offer advantages in terms of safety, scalability, and consistency. The ORF2-encoded capsid protein, which is the sole structural protein responsible for viral attachment, assembly, and immunogenicity, has been the primary target for subunit vaccine development [46, 72]. Wang et al. [46] developed a virus-like particle (VLP) vaccine against GAstV-1 using a baculovirus/insect cell expression system. The full-length ORF2 structural protein was efficiently expressed, with maximum expression observed at an MOI of 5 and 5 days post-infection. Importantly, the ORF2 protein underwent proteolytic cleavage, producing mature 40/43 kDa core and 25/27 kDa spike fragments, and self-assembled into VLPs of approximately 30 nm, accompanied by 10 nm ring-like structures. Immunization of goslings with as little as 5 μg of VLPs induced high levels of specific antibodies and a mixed Th1/Th2 immune response. Following challenge, viral shedding was significantly suppressed in immunized groups, with protection comparable to an inactivated virus vaccine. This study established a robust platform for GAstV-1 VLP production and demonstrated the strong immunogenicity and protective efficacy of VLPs, supporting their potential as a subunit vaccine.

The identification of specific B-cell epitopes within the capsid protein has facilitated the development of epitope-based vaccines and diagnostic tools. Li et al. [2] identified a novel linear B-cell epitope (¹⁵³NTAGPESIDT¹⁶²) in the GAstV-2 capsid protein that was highly conserved among GAstV-2 strains but showed only 90% similarity with turkey astrovirus 2 and less than 50% similarity with other astroviruses. Wang et al. [8] identified two novel linear B-cell epitopes (¹MADRA⁵ and ³⁶YKPQKLPMKA⁴⁵) in the conserved S domain of GAstV-2 ORF2, which were highly conserved among GAstV-2 isolates but demonstrated notable divergence from other avian astroviruses. Wang et al. [9] identified a GAstV-1-specific linear B-cell epitope (³⁹⁴SNREVQITQL⁴⁰³) within the conserved P1 domain of ORF2, which exhibited high conservation among GAstV-1 strains but marked divergence from GAstV-2 and other avian astroviruses. Yuan et al. [40] identified two novel neutralizing epitopes (⁴⁴³ESCSFLVF⁴⁵⁰ and ⁴²⁵QVTPSLVYNF⁴³⁴) in the P2 domain of the GAstV-2 capsid protein, which are critical for virus-receptor interactions and immune recognition. These epitopes provide potential targets for epitope-based vaccine design, where immunogenic peptides can be synthesized and formulated to induce specific neutralizing antibody responses without the complexity of producing full-length recombinant proteins.

Recombinant Vector Vaccines

Recombinant viral vector vaccines offer the advantage of delivering GAstV antigens in the context of a live viral vector that can induce both humoral and cellular immune responses, potentially providing more robust and durable protection than subunit vaccines. Chen et al. [72] developed a recombinant duck enteritis virus (DEV) vector expressing the GAstV ORF2 gene, aiming to create a bivalent vaccine capable of controlling both DEV and GAstV infections. Using Red E/T two-step recombinant technology, the GAstV ORF2 expression frame was inserted into the US7 and US8 intergenic region of the DEV genome within an infectious bacterial artificial chromosome clone. The recombinant virus, rDEV-GAstV ORF2, was rescued by transfecting the recombinant clone into chicken embryonic fibroblasts, and expression of the GAstV capsid protein was confirmed by Western blotting and immunofluorescence assay. Importantly, immunogold electron microscopy revealed the formation of virus-like particles within cells expressing the capsid protein, indicating that the recombinant vector could support proper folding and assembly of the GAstV structural protein. This approach leverages the well-established safety profile and immunogenicity of the DEV vaccine strain, potentially reducing development timelines and regulatory hurdles compared to entirely novel vaccine platforms.

The use of DEV as a vector offers several advantages for waterfowl vaccination. DEV vaccines have been widely used in duck and goose populations for decades, with established safety and efficacy profiles. The ability to deliver GAstV antigens in the context of a replicating viral vector may induce stronger and more durable immune responses compared to inactivated or subunit vaccines, particularly cellular immune responses that are important for controlling viral infections. Furthermore, the bivalent nature of the vaccine would simplify vaccination protocols, reducing labor costs and stress on birds associated with multiple vaccine administrations. However, the potential for pre-existing immunity to DEV in vaccinated flocks to interfere with the recombinant vaccine's efficacy must be carefully evaluated, as vector-specific immune responses could limit replication of the recombinant virus and reduce GAstV-specific immunogenicity.

mRNA Vaccine Technology

The revolutionary success of mRNA vaccines in combating the COVID-19 pandemic has spurred interest in applying this platform to veterinary vaccines, including those for GAstV. Zhao et al. [70] reported the first mRNA vaccine against GAstV, expressing the capsid protein delivered via lipid nanoparticles (LNPs). In mice, the vaccine elicited robust humoral and cellular immune responses, including high titers of GAstV-specific IgG, IgM, and neutralizing antibodies, significantly increased lymphocyte proliferation capacity, and a Th2-biased cytokine profile. In goslings, the vaccine induced neutralizing antibodies that peaked at four weeks post-immunization and significantly reduced viral shedding following challenge with a virulent GAstV strain. This proof-of-concept study demonstrated the feasibility of mRNA vaccine technology for GAstV control and highlighted several advantages of this platform, including rapid development and production, flexibility to update antigen sequences as new variants emerge, and the ability to induce both

References

[1] Ren D, Zhang H, Ye X, Jia X, Chen R, Tang T, et al.. Current Situation of Goose Astrovirus in China: A Review. Viruses. 2025. DOI: https://doi.org/10.3390/v17010084

[2] Li H, Huang H, Lin C, Zhang F, Tan J, Li N, et al.. Identification of a novel linear B-cell epitope recognized by a monoclonal antibody against the capsid protein of goose astrovirus genotypes 2. BMC Veterinary Research. 2025. DOI: https://doi.org/10.1186/s12917-025-04687-y

[3] Li M, Wang M, Wang J, Li H, Guan R, Yan G, et al.. Evolutionary and genotypic analyses of goose astrovirus. Poultry Science. 2025. DOI: https://doi.org/10.1016/j.psj.2025.105511

[4] Wang A, Wu Z, Zhou Q, Zhang X, Zhu Y, Xie J, et al.. Isolation, identification, and pathogenicity of a goose astrovirus 1 strain from goslings in Jiangsu province, China.. Microbial Pathogenesis. 2025. DOI: https://doi.org/10.1016/j.micpath.2025.107324

[5] Chen G, Yin L, Zhang H. Isolation and characterization of goose astrovirus genotype 1 causing enteritis in goslings from Sichuan Province, China. BMC Veterinary Research. 2025. DOI: https://doi.org/10.1186/s12917-025-04482-9

[6] Liu W, Wang J, Liu L, Sun X, Ji L, Yuan W, et al.. Development and application of a dual RT-qPCR assay for differentiating of goose astrovirus genotypes 1 and 2.. Research in Veterinary Science. 2025. DOI: https://doi.org/10.1016/j.rvsc.2025.105753

[7] Liu C, Li L, Dong J, Jin J, Xiang Y, Zhang J, et al.. Isolation, Characterization, and Comparative Analysis of Two Subtypes of Goose Astrovirus in Guangdong Province, China. Microorganisms. 2025. DOI: https://doi.org/10.3390/microorganisms13051037

[8] Wang A, Wu Z, Zhou Q, Zhang X, Liu L, Zhu S. Development of monoclonal antibodies against goose astrovirus 2 ORF2 protein and establishment of an indirect competitive ELISA detection method.. Journal of Virological Methods. 2025. DOI: https://doi.org/10.1016/j.jviromet.2025.115306

[9] Wang A, Liu L, Zhou Q, Zhang X, Wu Z, Zhu S. Characterization of a novel B-cell epitope in the structural protein of goose astrovirus 1 and its application in serological detection. Poultry Science. 2025. DOI: https://doi.org/10.1016/j.psj.2025.105674

[10] Li X, Yang W, Zhu M, Xu H, Yang J, Yi Z, et al.. Goose Astrovirus Type 2 Causes Intestinal Injury and Disrupts Homeostasis in Goslings. Veterinary Sciences. 2025. DOI: https://doi.org/10.3390/vetsci13010015

[11] Jiang P, Li A, Ma H, Lan Y, Wang J, Wang X, et al.. Genetic and structural factors contributing to the dominance and persistence of goose astrovirus type 2. Avian Pathology. 2025. DOI: https://doi.org/10.1080/03079457.2025.2454416

[12] Liu H, Sun R, Wu Y, Feng J, Fan G, Chen S, et al.. Molecular detection and identification of goose astrovirus in GuangDong Province, China.. Infection, Genetics and Evolution. 2025. DOI: https://doi.org/10.1016/j.meegid.2025.105745

[13] Man Y, Wang H, Xu X, Li D, Ji J, Yao L, et al.. Natural selection dominates the codon preference and host adaptability of the novel goose astrovirus related to gout symptons, with non-structural protein playing a key role. Poultry Science. 2025. DOI: https://doi.org/10.1016/j.psj.2025.106320

[14] Wei F, He D, Wu B, Diao Y, Tang Y. Isolation, Identification, and Pathogenicity of a Goose Astrovirus Genotype 1 Strain in Goslings in China. Viruses. 2024. DOI: https://doi.org/10.3390/v16040541

[15] Chen L, Cui H, Li J, Zhang Y, Wang H, Yang Y, et al.. Epidemiological Investigation of Goose Astrovirus in Hebei Province, China, 2019–2021. Microorganisms. 2024. DOI: https://doi.org/10.3390/microorganisms12050990

[16] Bi Z, Lv X, Zhang Z, Cai L, Zhang M, Li W, et al.. Emerging fatal gout disease in Chinese goslings linked to acute kidney injury induced by novel goose astrovirus infection. Frontiers in Cellular and Infection Microbiology. 2024. DOI: https://doi.org/10.3389/fcimb.2024.1470808

[17] Xu P, Wang X, Wang J, Liang J, Luo Y, Liu L, et al.. Isolation, identification, and pathogenicity of two novel goose astrovirus from goslings with severe gout in China.. Microbial Pathogenesis. 2024. DOI: https://doi.org/10.1016/j.micpath.2024.106829

[18] Zhou Q, Cui Y, Wang C, Wu H, Xiong H, Qi K, et al.. Characterization of natural co-infection with goose astrovirus genotypes I and II in gout affected goslings. Avian Pathology. 2023. DOI: https://doi.org/10.1080/03079457.2023.2295341

[19] Peng Z, Gao D, Song X, Huang H, Zhang X, Jiang Z, et al.. Isolation and genomic characterization of one novel goose astrovirus causing acute gosling gout in China. Scientific Reports. 2023. DOI: https://doi.org/10.1038/s41598-023-37784-9

[20] He D, Jiang X, Tian M, Niu X, Wei F, Wu B, et al.. Pathogenicity of goose astrovirus genotype 2 in chickens. Poultry Science. 2023. DOI: https://doi.org/10.1016/j.psj.2023.102808

[21] Zhang M, Wei X, Qian J, Yu Z, Liu X, Luo Y, et al.. Establishment and Application of Indirect ELISAs for Detecting Antibodies against Goose Astrovirus Genotype 1 and 2. Vaccines. 2023. DOI: https://doi.org/10.3390/vaccines11030664

[22] Zhu Q, Sun D. Goose Astrovirus in China: A Comprehensive Review. Viruses. 2022. DOI: https://doi.org/10.3390/v14081759

[23] Wang A, Zhang S, Xie J, Gu L, Wu S, Wu Z, et al.. Isolation and characterization of a goose astrovirus 1 strain causing fatal gout in goslings, China. Poultry Science. 2021. DOI: https://doi.org/10.1016/j.psj.2021.101432

[24] Liu C, Sun M, Liao M. A Review of Emerging Goose Astrovirus Causing Gout. BioMed Research International. 2022. DOI: https://doi.org/10.1155/2022/1635373

[25] Fei Z, Jiao A, Xu M, Wu J, Wang Y, Yu J, et al.. Genetic diversity and evolution of goose astrovirus in the east of China.. Transboundary and Emerging Diseases. 2022. DOI: https://doi.org/10.1111/tbed.14542

[26] Zhang F, Li H, Wei Q, Xie Q, Zeng Y, Wu C, et al.. Isolation and phylogenetic analysis of goose astrovirus type 1 from goslings with gout in Jiangxi province, China. Poultry Science. 2022. DOI: https://doi.org/10.1016/j.psj.2022.101800

[27] Yi Z, Ding R, Cao R, Sun W, Sun M, Dong Y, et al.. Development of a duplex TaqMan real-time RT-PCR assay for simultaneous detection of goose astrovirus genotypes 1 and 2.. Journal of Virological Methods. 2022. DOI: https://doi.org/10.1016/j.jviromet.2022.114542

[28] Wang H, Zhu Y, Ye W, Hua J, Chen L, Ni Z, et al.. Genomic and Epidemiological Characteristics Provide Insights into the Phylogeographic Spread of Goose Astrovirus in China.. Transboundary and Emerging Diseases. 2022. DOI: https://doi.org/10.1111/tbed.14522

[29] Fu X, Hou Z, Liu W, Cao N, Liang Y, Li B, et al.. Insight into the Epidemiology and Evolutionary History of Novel Goose Astrovirus-Associated Gout in Goslings in Southern China. Viruses. 2022. DOI: https://doi.org/10.3390/v14061306

[30] Ren Z, Zhang Q, Li J, Yu Z, Fu G, Liu R, et al.. Detection and Characterization of Goose Astrovirus Infections in Hatcheries and Commercial Goose Flocks. Transboundary and Emerging Diseases. 2023. DOI: https://doi.org/10.1155/2023/1127544

[31] Chen Q, Yu Z, Xu X, Ji J, Yao L, Kan Y, et al.. First report of a novel goose astrovirus outbreak in Muscovy ducklings in China. Poultry Science. 2021. DOI: https://doi.org/10.1016/j.psj.2021.101407

[32] He D, Sun M, Jiang X, Zhang S, Wei F, Wu B, et al.. Development of an indirect competitive ELISA method based on ORF2 detecting the antibodies of novel goose astrovirus.. Journal of Virological Methods. 2022. DOI: https://doi.org/10.1016/j.jviromet.2022.114643

[33] Ren D, Zhang X, Zhang W, Lian M, Meng X, Li T, et al.. A peptide-based ELISA for detection of antibodies against novel goose astrovirus type 1.. Journal of Virological Methods. 2022. DOI: https://doi.org/10.1016/j.jviromet.2022.114646

[34] Li J, Hu W, Liu T, Zhang H, Opriessnig T, Xiao C. Isolation and evolutionary analyses of gout-associated goose astrovirus causing disease in experimentally infected chickens. Poultry Science. 2020. DOI: https://doi.org/10.1016/j.psj.2020.11.003

[35] Chen H, Zhang B, Yan M, Diao Y, Tang Y. First report of a novel goose astrovirus outbreak in Cherry Valley ducklings in China.. Transboundary and Emerging Diseases. 2019. DOI: https://doi.org/10.1111/tbed.13418

[36] Dai G, Huang X, Liu Q, Li Y, Zhang L, Han K, et al.. Identification of a linear epitope in the capsid protein of goose astrovirus with monoclonal antibody.. Polish journal of veterinary sciences. 2022. DOI: https://doi.org/10.24425/pjvs.2022.143541

[37] Wei F, Yang J, Wang Y, Chen H, Diao Y, Tang Y. Isolation and characterization of a duck-origin goose astrovirus in China. Emerging Microbes and Infections. 2020. DOI: https://doi.org/10.1080/22221751.2020.1765704

[38] Zhang X, Ren D, Li T, Zhou H, Liu X, Wang X, et al.. An emerging novel goose astrovirus associated with gosling gout disease, China. Emerging Microbes and Infections. 2018. DOI: https://doi.org/10.1038/s41426-018-0153-7

[39] Yang J, Tian J, Tang Y, Diao Y. Isolation and genomic characterization of gosling gout caused by a novel goose astrovirus. Transboundary and Emerging Diseases. 2018. DOI: https://doi.org/10.1111/tbed.12928

[40] Yuan S, Fu R, Xu B, Wang W, Ding H, Pan X, et al.. Identification of novel B-cell neutralizing epitopes in goose Astrovirus type 2.. Veterinary Microbiology. 2026. DOI: https://doi.org/10.1016/j.vetmic.2026.110874

[41] Lv J, Liu Y, Liu Z, Wang Z, She W, Liu C, et al.. A Monoclonal Antibody-Based Indirect Competitive ELISA for Detecting Goose Astrovirus Antibodies. Veterinary Sciences. 2026. DOI: https://doi.org/10.3390/vetsci13010059

[42] Dong W, Lv H, Zhang X, Sheng Y, Wu Q, Li J, et al.. Identification and genomic characterization of a goose astrovirus in Henan Province, China. Frontiers in Veterinary Science. 2026. DOI: https://doi.org/10.3389/fvets.2026.1806778

[43] Zhai S, Li R, Liu K, Gao H, Yang X, Zhao J, et al.. Adenosine deaminase promotes goose astrovirus genotype II replication in GEF cells. Poultry Science. 2025. DOI: https://doi.org/10.1016/j.psj.2025.105176

[44] Qian L, Liu Y, Wang X, Yang S, Ji L, Sun X, et al.. Screening and identification of protein interacting with goose astrovirus. Frontiers in Cellular and Infection Microbiology. 2025. DOI: https://doi.org/10.3389/fcimb.2025.1595736

[45] Zhang X, Zhai S, Guo Y, Li R, Ma X, Liu Y, et al.. Genome-wide transcriptome analysis of gene expression profiles in Goose Astrovirus-infected GEF cells.. Microbial Pathogenesis. 2025. DOI: https://doi.org/10.1016/j.micpath.2025.107343

[46] Wang A, Wu Z, Liu L, Zhou Q, Cheng Y, Jia W, et al.. Self-assembly and immunogenicity of virus-like particles from goose astrovirus 1 structural protein following proteolytic maturation in a baculovirus system. Poultry Science. 2025. DOI: https://doi.org/10.1016/j.psj.2025.106037

[47] Li H, Su Q, Fu D, Huang H, Lu Z, Huang C, et al.. Alteration of gut microbiome in goslings infected with goose astrovirus. Poultry Science. 2024. DOI: https://doi.org/10.1016/j.psj.2024.103869

[48] Hou Z, Jin S, Liang Y, Wang H, Jiang D, Cao N, et al.. Apoptosis, inflammatory and innate immune responses induced by infection with a novel goose astrovirus in goose embryonic kidney cells. Frontiers in Cellular and Infection Microbiology. 2024. DOI: https://doi.org/10.3389/fcimb.2024.1452158

[49] Xiang Y, Li L, Huang Y, Zhang J, Dong J, Zhai Q, et al.. Cellular vimentin interacts with VP70 protein of goose astrovirus genotype 2 and acts as a structural organizer to facilitate viral replication. Poultry Science. 2024. DOI: https://doi.org/10.1016/j.psj.2024.104146

[50] Li R, Zhai S, Gao S, Yang X, Zhao J, Zhang X, et al.. Goose IFIT5 positively regulates goose astrovirus replication in GEF cells. Poultry Science. 2024. DOI: https://doi.org/10.1016/j.psj.2024.103930

[51] Lu Z, Li H, Gao X, Fu D, Huang H, Huang C, et al.. Goose astrovirus induces apoptosis and endoplasmic reticulum stress in gosling hepatocytes. Poultry Science. 2024. DOI: https://doi.org/10.1016/j.psj.2024.104600

[52] Zhu M, Guo Z, Xu H, Li X, Chen H, Cao R, et al.. Aminoguanidine alleviates gout in goslings experimentally infected with goose astrovirus-2 by reducing kidney lesions. Poultry Science. 2024. DOI: https://doi.org/10.1016/j.psj.2024.103484

[53] Ding R, Xu H, Huang H, Cao R, Lv Y. Effects of Goose Astrovirus Type 2 Infection on Peripheral Blood Lymphocyte and Macrophage Activity In Vitro. Viral immunology. 2024. DOI: https://doi.org/10.1089/vim.2023.0098

[54] Xu L, Jiang B, Cheng Y, He Y, Wu Z, Wang M, et al.. Infection and innate immune mechanism of goose astrovirus. Frontiers in Microbiology. 2023. DOI: https://doi.org/10.3389/fmicb.2023.1121763

[55] Wu W, Xu R, Lv Y, Bao E. Goose astrovirus infection affects uric acid production and excretion in goslings. Poultry Science. 2020. DOI: https://doi.org/10.1016/j.psj.2019.11.064

[56] Ren D, Li T, Zhang X, Yao X, Gao W, Xie Q, et al.. OASL Triggered by Novel Goose Astrovirus via ORF2 Restricts Its Replication. Journal of Virology. 2020. DOI: https://doi.org/10.1128/JVI.01767-20

[57] Wei F, Jiang X, He D, Wang Q, Diao Y, Tang Y. The Isolation and Characterization of Goose Astrovirus Genotype 2 from Laying Hens with Nephritis in Shandong Province, China. Transboundary and Emerging Diseases. 2023. DOI: https://doi.org/10.1155/2023/8515116

[58] Zhang X, Deng T, Song Y, Liu J, Jiang Z, Peng Z, et al.. Identification and genomic characterization of emerging goose astrovirus in central China, 2020.. Transboundary and Emerging Diseases. 2021. DOI: https://doi.org/10.1111/tbed.14060

[59] Niu X, Tian J, Yang J, Jiang X, Wang H, Chen H, et al.. Novel Goose Astrovirus Associated Gout in Gosling, China.. Veterinary Microbiology. 2018. DOI: https://doi.org/10.1016/j.vetmic.2018.05.006

[60] Wang Y, Bai C, Zhang D, Yang K, Yu Z, Jiang S, et al.. Genomic and phylogenetic characteristics of a novel goose astrovirus in Anhui Province, Central-Eastern China.. Gene. 2020. DOI: https://doi.org/10.1016/j.gene.2020.144898

[61] Yin C, Shi Y, Li H, Lu Z, Gao X, Hu G, et al.. Effects and potential pathways of goose astrovirus infection on gosling hepatic lipid metabolism. Frontiers in Microbiology. 2025. DOI: https://doi.org/10.3389/fmicb.2025.1531373

[62] Liu W, Wang J, Li X, Li T, Ji L, Shi Y, et al.. Development and application of a dual RT-qRPA assay for rapid differentiating of goose astrovirus genotypes 1 and 2. Poultry Science. 2025. DOI: https://doi.org/10.1016/j.psj.2025.105752

[63] Xu L, Wu Z, He Y, Jiang B, Cheng Y, Wang M, et al.. Molecular characterization of a virulent goose astrovirus genotype-2 with high mortality in vitro and in vivo. Poultry Science. 2024. DOI: https://doi.org/10.1016/j.psj.2024.103585

[64] Li H, Kang Z, Wan C, Zhang F, Tan M, Zeng Y, et al.. Rapid diagnosis of different goose astrovirus genotypes with Taqman-based duplex real-time quantitative PCR. Poultry Science. 2023. DOI: https://doi.org/10.1016/j.psj.2023.102730

[65] Wang A, Xie J, Wu Z, Liu L, Wu S, Feng Q, et al.. Pathogenicity of a goose astrovirus 2 strain causing fatal gout in goslings.. Microbial Pathogenesis. 2023. DOI: https://doi.org/10.1016/j.micpath.2023.106341

[66] Wei F, Jiang X, He D, Diao Y, Tang Y. Localization and distribution of goose astrovirus 2 antigens in different tissues at different times. BMC Veterinary Research. 2023. DOI: https://doi.org/10.1186/s12917-023-03688-z

[67] Zhu Y, Wang H, Hua J, Ye W, Chen L, Ni Z, et al.. Isolation and Pathogenicity of a Novel Goose Astrovirus from Overfed Adult Landaise Geese in China. Viruses. 2022. DOI: https://doi.org/10.3390/v14122806

[68] Wang A, Liu L, Zhang S, Ye W, Zheng T, Xie J, et al.. Development of a duplex real-time reverse transcription-polymerase chain reaction assay for the simultaneous detection of goose astrovirus genotypes 1 and 2.. Journal of Virological Methods. 2022. DOI: https://doi.org/10.1016/j.jviromet.2022.114612

[69] Zhu Q, Miao Y, Wang J, Bai W, Yang X, Yu S, et al.. Isolation, identification, and pathogenicity of a goose astrovirus causing fatal gout in goslings.. Veterinary Microbiology. 2022. DOI: https://doi.org/10.1016/j.vetmic.2022.109570

[70] Zhao D, Huang X, Zhang L, Han K, Yang J, Lu F, et al.. An mRNA vaccine expressing the capsid protein of goose astrovirus elicits protective immunity.. Veterinary Microbiology. 2025. DOI: https://doi.org/10.1016/j.vetmic.2025.110812

[71] Zhang M, Lv X, Wang B, Yu S, Lu Q, Kan Y, et al.. Development of a potential diagnostic monoclonal antibody against capsid spike protein VP27 of the novel goose astrovirus. Poultry Science. 2021. DOI: https://doi.org/10.1016/j.psj.2021.101680

[72] Chen L, Zhu Y, Yun T, Ye W, Ni Z, Hua J, et al.. In vitro expression of the goose astrovirus Cap protein delivered with a duck enteritis virus vector. BMC Veterinary Research. 2025. DOI: https://doi.org/10.1186/s12917-025-04654-7

[73] Wang D, Ji Y, Liu B, Yan L, Ai Y, Wang J, et al.. On-Site Rapid and Specific Detection of Novel Emerging Goose Astrovirus Using a Nanobody-Based Colloidal Gold Immunochromatographic Strip. Transboundary and Emerging Diseases. 2025. DOI: https://doi.org/10.1155/tbed/6439771

[74] Zheng L, Zhang H. A reverse transcription recombinase-aided amplification assay for the rapid detection of goose astrovirus. Veterinary Research Forum. 2025. DOI: https://doi.org/10.30466/vrf.2024.2034344.4346

[75] Xu P, Lu J, Chen L, Chen X, Lu Z, Ye M, et al.. Development of a chicken egg yolk antibody (IgY) could effectively prevent and treat goose astrovirus infection.. Vaccine. 2025. DOI: https://doi.org/10.1016/j.vaccine.2025.127167

[76] Zhu Y, Chen L, Xu X, Ye W, Ni Z, Huo S, et al.. Development of a multienzyme isothermal and lateral flow dipstick combination assay for the rapid detection of goose astrovirus II. Frontiers in Cellular and Infection Microbiology. 2024. DOI: https://doi.org/10.3389/fcimb.2024.1424212

[77] Li H, Zhu Y, Wan C, Wang Z, Liu L, Tan M, et al.. Rapid detection of goose astrovirus genotypes 2 using real-time reverse transcription recombinase polymerase amplification. BMC Veterinary Research. 2023. DOI: https://doi.org/10.1186/s12917-023-03790-2

[78] Yang K, Zhang W, Xu L, Liu Q, Song X, Shao Y, et al.. Facile, ultrasensitive, and highly specific diagnosis of goose astrovirus via reverse transcription-enzymatic recombinase amplification coupled with a CRISPR-Cas12a system detection. Poultry Science. 2022. DOI: https://doi.org/10.1016/j.psj.2022.102208